metoclopramide has been researched along with Neoplasms in 163 studies
Metoclopramide: A dopamine D2 antagonist that is used as an antiemetic.
metoclopramide : A member of the class of benzamides resulting from the formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with the primary amino group of N,N-diethylethane-1,2-diamine.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The granisetron group indicated a higher complete response rate in acute emesis (adjusted OR: 0." | 9.17 | Can granisetron injection used as primary prophylaxis improve the control of nausea and vomiting with low- emetogenic chemotherapy? ( Abdul Kassim, MS; Keat, CH; Phua, G; Poh, WK; Sriraman, M, 2013) |
| "During the 72-h observation period, 39 out of 56 (70%) patients receiving olanzapine had no emesis compared to 16 out of 52 (31%) patients with no emesis for patients receiving metoclopramide (p < 0." | 9.17 | The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. ( Gray, SE; Nagy, CK; Navari, RM, 2013) |
| "In low dose cisplatin regimen, complete suppression of delayed emesis occurred in 55 per cent patients receiving ondansetron and in 30 per cent patients receiving metoclopramide." | 9.11 | Efficacy & tolerability of ondansetron compared to metoclopramide in dose dependent cisplatin-induced delayed emesis. ( Bhatia, A; Sharma, M; Tripathi, KD, 2004) |
| "In daily practice, a combination of oral dexamethasone and oral granisetron achieves an extremely high control of acute emesis (86% protection)." | 9.10 | A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis. ( Aapro, MS; Bernhard, J; De Pree, C; Maibach, R; Sessa, C; Thuerlimann, B, 2003) |
| " The present study aimed to study the efficacy and tolerability of ondansetron versus (vs) metoclopramide in different dose related grades of cisplatin induced acute emesis." | 9.10 | Comparison of ondansetron with metoclopramide in prevention of acute emesis associated with low dose & high dose cisplatin chemotherapy. ( Bhatia, A; Sharma, M; Tripathi, KD, 2003) |
| "Of the patients treated with metoclopramide plus methylprednisolone (n = 92), 53% had complete protection from delayed emesis, 16% a major response, 15% a minor response, and 15% no response." | 9.08 | Oral granisetron with or without methylprednisolone versus metoclopramide plus methylprednisolone in the management of delayed nausea and vomiting induced by cisplatin-based chemotherapy. A prospective randomized trial. ( Cannata, G; Gebbia, N; Gebbia, V; Testa, A; Tirrito, ML; Valenza, R, 1995) |
| "The purpose of this retrospective study is to assess the frequency and intensity of chronic nausea in patients admitted to the Palliative Care Unit and the results of a metoclopramide-based treatment regimen." | 9.08 | Chronic nausea in advanced cancer patients: a retrospective assessment of a metoclopramide-based antiemetic regimen. ( Babul, N; Bruera, E; Darke, A; Harsanyi, Z; Seifert, L; Suarez-Almazor, M; Watanabe, S, 1996) |
| "The potent serotonin receptor (5-HT3) antagonists are new highly selective agents for the prevention and control of chemotherapy-induced nausea and vomiting that have been shown to be comparable to or more effective than traditional metoclopramide regimens." | 9.08 | A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy. ( Bastit, P; Cals, L; Cappelaere, P; Catimel, G; Chevallier, B; Claverie, N; Fabbro, M; Giovannini, M; Khayat, D; Splinter, T; Wendling, JL, 1997) |
| "A single institution, prospective, randomized trial was performed in terminal cancer patients to compare tropisetron (TRO), metoclopramide (MET), and chlorpromazine (CHL) in the management of nausea and emesis." | 9.08 | Comparison of the efficacy and safety of tropisetron, metoclopramide, and chlorpromazine in the treatment of emesis associated with far advanced cancer. ( Befon, S; Liossi, C; Mystakidou, K; Vlachos, L, 1998) |
| "The short elimination half-life of metoclopramide necessitates frequent administration for optimal relief of nausea." | 9.07 | Comparison of the efficacy, safety, and pharmacokinetics of controlled release and immediate release metoclopramide for the management of chronic nausea in patients with advanced cancer. ( Babul, N; Bruera, ED; Darke, AC; Harsanyi, Z; LeGatt, DF; MacDonald, RN; MacEachern, TJ; Spachynski, KA, 1994) |
| ", Basel, Switzerland), a new 5-HT3 receptor antagonist, was compared in a randomized multicenter trial with a high-dose metoclopramide-dexamethasone cocktail for the prevention of nausea and emesis during cisplatin-containing chemotherapy." | 9.07 | A randomized, multicenter study comparing the efficacy and tolerability of tropisetron, a new 5-HT3 receptor antagonist, with a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis. ( de Bruijn, KM; Glimelius, B; Hansen, O; Högberg, T; Räisänen, I; Schmidt, M; Sorbe, BG; Sörensen, BT; van Oosterom, AT; Wernstedt, L, 1994) |
| "This report of a double-blind, randomized study performed to evaluate the comparative antiemetic efficacy of tropisetron (Navoban; Sandoz Pharma Ltd, Basel, Switzerland), a new 5-hydroxytryptamine receptor antagonist, focuses on treatment during stages of chemotherapy when nausea and vomiting are particularly severe." | 9.07 | A report comparing the use of tropisetron (Navoban), a 5-HT3 antagonist, with a standard antiemetic regimen of dexamethasone and metoclopramide in cisplatin-treated patients under conditions of severe emesis. ( Krzakowski, M; Lasota, W; Madej, G; Pawinski, A; Rogowski, W; Skoneczna, I, 1994) |
| "The efficacy and tolerability of tropisetron in preventing cisplatin-induced nausea and vomiting was studied in 2 open trials and compared with the efficacy and tolerability of metoclopramide plus lorazepam in a randomised crossover trial." | 9.07 | Three years' experience with tropisetron in the control of nausea and vomiting in cisplatin-treated patients. ( Antonacci, RA; Berruti, A; Dogliotti, L; Faggiuolo, R; Ortega, C; Pazè, E, 1992) |
| "This double-blind randomized cross-over study was conducted to compare the safety and efficacy of high-dose prochlorperazine infusion and dexamethasone (HDPD) with an effective and safe combination of high-dose metoclopramide and dexamethasone (HDMD) in controlling cisplatin-induced emesis." | 9.07 | A double-blind randomized cross-over comparison of high-dose prochlorperazine with high-dose metoclopramide for cisplatin-induced emesis. ( Akhtar, SS; Bano, ZA; Bhat, GM; Bhat, MA, 1991) |
| "Thirty three untreated patients being given cisplatin received metoclopramide (7 mg/kg) for antiemesis by either continuous or intermittent infusion in a random order." | 9.06 | Optimising antiemesis in cancer chemotherapy: efficacy of continuous versus intermittent infusion of high dose metoclopramide in emesis induced by cisplatin. ( Allan, SG; Cornbleet, MA; Leonard, RC; MacPherson, JS; Smyth, JF; Warrington, PS, 1986) |
| " Compared to metoclopramide, alizapride caused a faster regression of inappetence and of the frequency of daily vomiting." | 9.05 | [Alizapride in a double-blind trial with metoclopramide in nausea and vomiting caused by radiotherapy]. ( Budach, V; Krüger, K, 1983) |
| "The effect of high-dose metoclopramide (2 mg/kg, 4 times every 2 hours) on the emesis of patients treated with CDDP (80 mg/m2) was examined by randomized control trial." | 9.05 | [Randomized control study of high-dose metoclopramide in the prevention of CDDP-induced emesis]. ( Eguchi, K; Fujita, J; Funaki, Y; Futami, H; Sakurai, M; Sasaki, Y; Sawamura, N; Takahashi, S; Yokoyama, S; Yoshioka, S, 1985) |
| "We tested the safety and antiemetic effectiveness of intravenous (IV) dexamethasone (DXM) as an adjunct to high-dose IV metoclopramide (MCP) to prevent nausea and vomiting induced by high-dose cisplatin chemotherapy." | 9.05 | High-dose intravenous metoclopramide versus combination high-dose metoclopramide and intravenous dexamethasone in preventing cisplatin-induced nausea and emesis: a single-blind crossover comparison of antiemetic efficacy. ( Liponi, DF; McDermed, JE; Strum, SB, 1985) |
| "To assess the efficacy and safety of olanzapine when used as an antiemetic in the prevention and treatment of nausea and vomiting related to cancer in adults." | 8.98 | Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults. ( Burton, MJ; Head, K; Naessens, K; Plugge, E; Sutherland, A; Ware, L; Wee, B, 2018) |
| " Delayed emesis following Cycle 1 of carboplatin was observed in 30% of patients." | 7.83 | Delayed nausea and vomiting from carboplatin doublet chemotherapy. ( Baggstrom, MQ; Chitneni, P; Gao, F; Govindan, R; Mann, J; Morgensztern, D; Waqar, MA; Waqar, SN; Williams, K, 2016) |
| "Patients with cancer frequently report gastrointestinal symptoms such as anorexia, early satiety, nausea, vomiting, and bloating." | 7.80 | Long-term safety and clinical effectiveness of controlled-release metoclopramide in cancer-associated dyspepsia syndrome: a multicentre evaluation. ( Chow, W; Darke, A; Harsanyi, Z; Marshall, D; Pearen, S; Plourde, JY; Wilson, J; Yoshida, S, 2002) |
| "Fifty-one patients who received their first course of chemotherapy were studied to compare the respective efficacy and safety of granisetron and metoclopramide plus dexamethasone in the prevention of nausea and vomiting induced by emetogenic cytotoxic drugs." | 7.69 | Comparison of intravenous granisetron with metoclopramide plus dexamethasone in the prevention of nausea and vomiting associated with emetogenic cytotoxic chemotherapy. ( Chang, CS; Chen, LT; Chen, TP; Huang, SM; Lin, SF; Liu, TC; Wei, TC, 1997) |
| "Repeated oral doses of metoclopramide (50 mg) and prednisone (25 mg) completely prevented nausea and vomiting (N + V) in approximately 50% and substantially reduced N + V in an additional 27%-36% of 56 chemotherapy courses in 30 consecutive cancer patients who were receiving primarily cisplatin." | 7.67 | Effective control of chemotherapy-induced nausea and vomiting with oral prednisone and metoclopramide. ( Bachmann-Mettler, I; Glaus, A; Senn, HJ, 1984) |
| "Nausea and emesis are common side effects of opioid drugs administered for pain relief in cancer patients." | 6.70 | A double-blind, randomised, parallel group, multinational, multicentre study comparing a single dose of ondansetron 24 mg p.o. with placebo and metoclopramide 10 mg t.d.s. p.o. in the treatment of opioid-induced nausea and emesis in cancer patients. ( Albertsson, M; Chimontsi-Kypriou, V; Curtis, P; Daly, S; Hardy, J; McQuade, B; Stathopoulos, P, 2002) |
| " Tropisetron in combination with dexamethasone produced the best control of both acute and delayed emesis." | 6.67 | Prevention of chemotherapy-induced nausea and vomiting by tropisetron (Navoban) alone or in combination with other antiemetic agents. ( Bruntsch, U; Drechsler, S; Eggert, J; Faerber, L; Gosse, H; Imhoff, W; Ukena, D, 1994) |
| "Emesis is one of the most frequent and distressing adverse effects of cytotoxic chemotherapy." | 6.67 | Prevention of emesis by tropisetron (Navoban) in children receiving cytotoxic therapy for solid malignancies. ( Balduck, N; Hachimi-Idrissi, S; Maurus, R; Otten, J, 1994) |
| "Acute nausea was prevented completely in 40% of patients in the tropisetron group and in 61% of the metoclopramide cocktail group during course 1 (P < ." | 6.67 | Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience. ( Sorbe, BG, 1994) |
| "289 consecutive cancer patients receiving cisplatin chemotherapy (much greater than 50 mg/m2) were randomised to receive one of the following intravenous antiemetic regimens: ondansetron 0." | 6.67 | Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis. Italian Group For Antiemetic Research. ( , 1992) |
| "Continuous infusion of metoclopramide was compared with bolus dosing in a randomized, double-blind study in 27 patients receiving cisplatin therapy." | 6.66 | Continuous i.v. infusion versus multiple bolus doses of metoclopramide for prevention of cisplatin-induced emesis. ( Agostinucci, WA; Dinonno, EB; Gannon, RH; Golub, GR; Martin, RS; Schauer, PK, 1988) |
| "In a randomized trial of 58 cancer patients receiving strongly emetogenic cytostatic drugs (cisplatin or comparable cytostatic agents, alone or in combination), the anti-emetic action of oral metoclopramide was tested, alone or combined with prednisone." | 6.66 | [Prevention of nausea and emesis during cytostatic therapy. Antiemetic efficacy of high-dosage oral metoclopramide without and with prednisone]. ( Bachmann-Mettler, I; Glaus, A; Köhler, M; Senn, HJ; Weigand, W, 1986) |
| "In a population of 51 ambulant cancer patients treated with doxorubicin-containing chemotherapy we conducted a double-blind cross-over randomized trial, comparing the anti-emetic efficacy of a combination of amitriptyline (25 mg p." | 6.65 | Amitriptyline plus fluphenazine to prevent chemotherapy-induced emesis in cancer patients: a double-blind randomized cross-over study. ( Blijham, GH; Mellink, WA; van Deyk, WA, 1984) |
| "Metoclopramide was superior to placebo and to prochlorperazine in reducing the volume of emesis (P = 0." | 6.65 | Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. ( Bordin, LA; Braun, DW; Braun, TJ; Gralla, RJ; Itri, LM; Kelsen, DP; Pisko, SE; Squillante, AE; Young, CW, 1981) |
| " The importance of adequate dosage of metoclopramide and the role of IV metoclopramide are emphasized." | 6.65 | Metoclopramide in the reduction of nausea and vomiting associated with combined chemotherapy. ( Cox, R; Leyland, MJ; Newman, CE, 1982) |
| "Metoclopramide is a very effective drug in preventing the acute emetic and nauseating effects of cisplatin." | 5.28 | Suitability of long-acting metoclopramide for prophylaxis of chemotherapy-induced delayed nausea and vomiting. ( Schimke, J; Senn, HJ; Vergin, H; Wilder-Smith, C, 1989) |
| " Metoclopramide and methylprednisolone, at the dosage and schedule used, were well tolerated and moderately active in preventing nausea and vomiting induced by cis-platin; their use in combination could further improve these results." | 5.27 | Comparison of methylprednisolone and metoclopramide in the prophylactic treatment of cis-platin-induced nausea and vomiting. ( Bertetto, O; Calciati, A; Ciuffreda, L; Clerico, M; Donadio, M; Ferrati, P; Giaccone, G; Musella, R, 1984) |
| " The quantitative dose-response curves of the four doses of the emetic agonist cisplatin were shifted to the right by increasing doses of MCL." | 5.27 | Dose-response relationships of the objective and subjective antiemetic effects and of different side effects of metoclopramide against cisplatin induced emesis. ( Hellenbrecht, D; Saller, R, 1986) |
| " The granisetron group indicated a higher complete response rate in acute emesis (adjusted OR: 0." | 5.17 | Can granisetron injection used as primary prophylaxis improve the control of nausea and vomiting with low- emetogenic chemotherapy? ( Abdul Kassim, MS; Keat, CH; Phua, G; Poh, WK; Sriraman, M, 2013) |
| "During the 72-h observation period, 39 out of 56 (70%) patients receiving olanzapine had no emesis compared to 16 out of 52 (31%) patients with no emesis for patients receiving metoclopramide (p < 0." | 5.17 | The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. ( Gray, SE; Nagy, CK; Navari, RM, 2013) |
| "Several trials had independently noted that patients receiving megestrol acetate had less nausea and vomiting, but this antiemetic activity of megestrol acetate has not been reported separately in the literature." | 5.15 | Antiemetic activity of megestrol acetate in patients receiving chemotherapy. ( Bi, F; Cao, D; Gou, HF; Hou, M; Jiang, M; Luo, de Y; Qiu, M; Shen, Y; Wang, J; Xu, F; Yang, Y; Yi, C; Zang, J; Zhou, XJ, 2011) |
| "First-line antiemetics for nausea and vomiting in advanced cancer are metoclopramide and haloperidol, and second-line medications are methotrimeprazine and olanzapine." | 5.12 | MASCC antiemetics in advanced cancer updated guideline. ( Bruera, E; Capela, A; Davies, A; Davis, M; DeFeo, G; Del Fabbro, E; Hui, D; Ripamonti, C, 2021) |
| "In low dose cisplatin regimen, complete suppression of delayed emesis occurred in 55 per cent patients receiving ondansetron and in 30 per cent patients receiving metoclopramide." | 5.11 | Efficacy & tolerability of ondansetron compared to metoclopramide in dose dependent cisplatin-induced delayed emesis. ( Bhatia, A; Sharma, M; Tripathi, KD, 2004) |
| "In daily practice, a combination of oral dexamethasone and oral granisetron achieves an extremely high control of acute emesis (86% protection)." | 5.10 | A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis. ( Aapro, MS; Bernhard, J; De Pree, C; Maibach, R; Sessa, C; Thuerlimann, B, 2003) |
| " The present study aimed to study the efficacy and tolerability of ondansetron versus (vs) metoclopramide in different dose related grades of cisplatin induced acute emesis." | 5.10 | Comparison of ondansetron with metoclopramide in prevention of acute emesis associated with low dose & high dose cisplatin chemotherapy. ( Bhatia, A; Sharma, M; Tripathi, KD, 2003) |
| "Of the patients treated with metoclopramide plus methylprednisolone (n = 92), 53% had complete protection from delayed emesis, 16% a major response, 15% a minor response, and 15% no response." | 5.08 | Oral granisetron with or without methylprednisolone versus metoclopramide plus methylprednisolone in the management of delayed nausea and vomiting induced by cisplatin-based chemotherapy. A prospective randomized trial. ( Cannata, G; Gebbia, N; Gebbia, V; Testa, A; Tirrito, ML; Valenza, R, 1995) |
| "The purpose of this retrospective study is to assess the frequency and intensity of chronic nausea in patients admitted to the Palliative Care Unit and the results of a metoclopramide-based treatment regimen." | 5.08 | Chronic nausea in advanced cancer patients: a retrospective assessment of a metoclopramide-based antiemetic regimen. ( Babul, N; Bruera, E; Darke, A; Harsanyi, Z; Seifert, L; Suarez-Almazor, M; Watanabe, S, 1996) |
| "The potent serotonin receptor (5-HT3) antagonists are new highly selective agents for the prevention and control of chemotherapy-induced nausea and vomiting that have been shown to be comparable to or more effective than traditional metoclopramide regimens." | 5.08 | A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy. ( Bastit, P; Cals, L; Cappelaere, P; Catimel, G; Chevallier, B; Claverie, N; Fabbro, M; Giovannini, M; Khayat, D; Splinter, T; Wendling, JL, 1997) |
| "A single institution, prospective, randomized trial was performed in terminal cancer patients to compare tropisetron (TRO), metoclopramide (MET), and chlorpromazine (CHL) in the management of nausea and emesis." | 5.08 | Comparison of the efficacy and safety of tropisetron, metoclopramide, and chlorpromazine in the treatment of emesis associated with far advanced cancer. ( Befon, S; Liossi, C; Mystakidou, K; Vlachos, L, 1998) |
| "The short elimination half-life of metoclopramide necessitates frequent administration for optimal relief of nausea." | 5.07 | Comparison of the efficacy, safety, and pharmacokinetics of controlled release and immediate release metoclopramide for the management of chronic nausea in patients with advanced cancer. ( Babul, N; Bruera, ED; Darke, AC; Harsanyi, Z; LeGatt, DF; MacDonald, RN; MacEachern, TJ; Spachynski, KA, 1994) |
| ", Basel, Switzerland), a new 5-HT3 receptor antagonist, was compared in a randomized multicenter trial with a high-dose metoclopramide-dexamethasone cocktail for the prevention of nausea and emesis during cisplatin-containing chemotherapy." | 5.07 | A randomized, multicenter study comparing the efficacy and tolerability of tropisetron, a new 5-HT3 receptor antagonist, with a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis. ( de Bruijn, KM; Glimelius, B; Hansen, O; Högberg, T; Räisänen, I; Schmidt, M; Sorbe, BG; Sörensen, BT; van Oosterom, AT; Wernstedt, L, 1994) |
| "This report of a double-blind, randomized study performed to evaluate the comparative antiemetic efficacy of tropisetron (Navoban; Sandoz Pharma Ltd, Basel, Switzerland), a new 5-hydroxytryptamine receptor antagonist, focuses on treatment during stages of chemotherapy when nausea and vomiting are particularly severe." | 5.07 | A report comparing the use of tropisetron (Navoban), a 5-HT3 antagonist, with a standard antiemetic regimen of dexamethasone and metoclopramide in cisplatin-treated patients under conditions of severe emesis. ( Krzakowski, M; Lasota, W; Madej, G; Pawinski, A; Rogowski, W; Skoneczna, I, 1994) |
| "The efficacy and tolerability of tropisetron in preventing cisplatin-induced nausea and vomiting was studied in 2 open trials and compared with the efficacy and tolerability of metoclopramide plus lorazepam in a randomised crossover trial." | 5.07 | Three years' experience with tropisetron in the control of nausea and vomiting in cisplatin-treated patients. ( Antonacci, RA; Berruti, A; Dogliotti, L; Faggiuolo, R; Ortega, C; Pazè, E, 1992) |
| " Costs, effects and cost-effectiveness of ondansetron in the prophylaxis of acute nausea and vomiting induced by chemotherapy are assessed relative to antiemetic therapy with metoclopramide." | 5.07 | Economic evaluation of ondansetron: preliminary analysis using clinical trial data prior to price setting. ( Buxton, MJ; O'Brien, BJ, 1992) |
| "This double-blind randomized cross-over study was conducted to compare the safety and efficacy of high-dose prochlorperazine infusion and dexamethasone (HDPD) with an effective and safe combination of high-dose metoclopramide and dexamethasone (HDMD) in controlling cisplatin-induced emesis." | 5.07 | A double-blind randomized cross-over comparison of high-dose prochlorperazine with high-dose metoclopramide for cisplatin-induced emesis. ( Akhtar, SS; Bano, ZA; Bhat, GM; Bhat, MA, 1991) |
| "Thirty three untreated patients being given cisplatin received metoclopramide (7 mg/kg) for antiemesis by either continuous or intermittent infusion in a random order." | 5.06 | Optimising antiemesis in cancer chemotherapy: efficacy of continuous versus intermittent infusion of high dose metoclopramide in emesis induced by cisplatin. ( Allan, SG; Cornbleet, MA; Leonard, RC; MacPherson, JS; Smyth, JF; Warrington, PS, 1986) |
| " A combination of Nabilone and metoclopramide was used in an unrandomized pilot study (prior to the withdrawal of Nabilone from clinical use); these patients recorded better scores for nausea and vomiting and patient acceptability than those in the randomized study." | 5.05 | Antiemetics for patients treated with antitumor chemotherapy. ( Bolton, A; de Pemberton, R; Whitehouse, JM; Williams, CJ, 1980) |
| "Metoclopramide is an effective antiemetic for cisplatin-induced vomiting when given in parenteral high-dose regimens but not oral low-dose regimens." | 5.05 | Comparison of the antiemetic effect of high-dose intravenous metoclopramide and high-dose intravenous haloperidol in a randomized double-blind crossover study. ( Cariffe, P; Gala, KV; Grunberg, SM; Jamin, D; Johnson, K; Krailo, M; Lampenfeld, M; Strych, D, 1984) |
| " Compared to metoclopramide, alizapride caused a faster regression of inappetence and of the frequency of daily vomiting." | 5.05 | [Alizapride in a double-blind trial with metoclopramide in nausea and vomiting caused by radiotherapy]. ( Budach, V; Krüger, K, 1983) |
| "The effect of high-dose metoclopramide (2 mg/kg, 4 times every 2 hours) on the emesis of patients treated with CDDP (80 mg/m2) was examined by randomized control trial." | 5.05 | [Randomized control study of high-dose metoclopramide in the prevention of CDDP-induced emesis]. ( Eguchi, K; Fujita, J; Funaki, Y; Futami, H; Sakurai, M; Sasaki, Y; Sawamura, N; Takahashi, S; Yokoyama, S; Yoshioka, S, 1985) |
| "Using a sensitive and specific high-pressure liquid chromatographic (HPLC) assay, we measured serum levels of metoclopramide in 18 cancer patients receiving high-dose intravenous (IV) therapy to prevent cisplatin-induced emesis." | 5.05 | Clinical pharmacokinetics of high-dose metoclopramide in cancer patients receiving cisplatin therapy. ( Cohen, JL; Joseph, C; McDermed, JE; Strum, SB, 1985) |
| "We tested the safety and antiemetic effectiveness of intravenous (IV) dexamethasone (DXM) as an adjunct to high-dose IV metoclopramide (MCP) to prevent nausea and vomiting induced by high-dose cisplatin chemotherapy." | 5.05 | High-dose intravenous metoclopramide versus combination high-dose metoclopramide and intravenous dexamethasone in preventing cisplatin-induced nausea and emesis: a single-blind crossover comparison of antiemetic efficacy. ( Liponi, DF; McDermed, JE; Strum, SB, 1985) |
| "To assess the efficacy and safety of olanzapine when used as an antiemetic in the prevention and treatment of nausea and vomiting related to cancer in adults." | 4.98 | Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults. ( Burton, MJ; Head, K; Naessens, K; Plugge, E; Sutherland, A; Ware, L; Wee, B, 2018) |
| "Ondansetron is more effective than high-dose metoclopramide in the prevention of acute nausea and vomiting due to highly emetogenic chemotherapy, and, unlike metoclopramide, is rarely associated with extrapyramidal effects." | 4.78 | Ondansetron: a pharmacoeconomic and quality-of-life evaluation of its antiemetic activity in patients receiving cancer chemotherapy. ( Milne, RJ; Plosker, GL, 1992) |
| " Although past attempts to reverse anorexia-cachexia have generally been disappointing, several promising new pharmacologic approaches are currently being evaluated, including megestrol acetate, hydrazine sulfate, metoclopramide, and dronabinol." | 4.78 | Management of anorexia-cachexia associated with cancer and HIV infection. ( Gorter, R, 1991) |
| " Common etiologies included constipation, opioid use, and "other," and treatments associated with a statistically significant decrease in nausea/vomiting were olanzapine, laxatives, corticosteroids, domperidone, and metoclopramide." | 3.91 | The nature of nausea: prevalence, etiology, and treatment in patients with advanced cancer not receiving antineoplastic treatment. ( Frandsen, K; Groenvold, M; Harder, S; Herrstedt, J; Isaksen, J; Jespersen, BA; Mondrup, L; Neergaard, MA; Sigaard, J, 2019) |
| " Delayed emesis following Cycle 1 of carboplatin was observed in 30% of patients." | 3.83 | Delayed nausea and vomiting from carboplatin doublet chemotherapy. ( Baggstrom, MQ; Chitneni, P; Gao, F; Govindan, R; Mann, J; Morgensztern, D; Waqar, MA; Waqar, SN; Williams, K, 2016) |
| "Patients with cancer frequently report gastrointestinal symptoms such as anorexia, early satiety, nausea, vomiting, and bloating." | 3.80 | Long-term safety and clinical effectiveness of controlled-release metoclopramide in cancer-associated dyspepsia syndrome: a multicentre evaluation. ( Chow, W; Darke, A; Harsanyi, Z; Marshall, D; Pearen, S; Plourde, JY; Wilson, J; Yoshida, S, 2002) |
| "While providing a better efficacy in acute emesis control, the low incidence of acute emesis and high ICER makes use of granisetron as primary prophylaxis in LEC controversial." | 3.79 | Cost-effectiveness analysis of granisetron-based versus standard antiemetic regimens in low-emetogenic chemotherapy: a hospital-based perspective from Malaysia. ( Ghani, NA; Keat, CH, 2013) |
| " Ondansetron 8 mg and dexamethasone 8 mg intravenously were the standard antiemetic therapy for prevention of acute chemotherapy-induced nausea and vomiting." | 3.77 | Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy. ( Baak-Pablo, RF; Gelderblom, H; Guchelaar, HJ; Hakimi, M; Mustofa, M; Nortier, JW; Perwitasari, DA; van der Straaten, RJ; Wessels, JA, 2011) |
| "We evaluated the antiemetic efficacy of tropisetron, a 5-HT3 receptor antagonist, during its compassionate use in children with malignant disease who during previous chemotherapy cycles experienced emesis refractory to metoclopramide-based treatments." | 3.69 | Tropisetron (ICS 205-930) in pediatric oncology: first results in patients refractory to antiemetic metoclopramide-based treatments. ( Armiraglio, A; Cefalo, G; Pagan, MG; Rottoli, L, 1994) |
| "Fifty-one patients who received their first course of chemotherapy were studied to compare the respective efficacy and safety of granisetron and metoclopramide plus dexamethasone in the prevention of nausea and vomiting induced by emetogenic cytotoxic drugs." | 3.69 | Comparison of intravenous granisetron with metoclopramide plus dexamethasone in the prevention of nausea and vomiting associated with emetogenic cytotoxic chemotherapy. ( Chang, CS; Chen, LT; Chen, TP; Huang, SM; Lin, SF; Liu, TC; Wei, TC, 1997) |
| "Repeated oral doses of metoclopramide (50 mg) and prednisone (25 mg) completely prevented nausea and vomiting (N + V) in approximately 50% and substantially reduced N + V in an additional 27%-36% of 56 chemotherapy courses in 30 consecutive cancer patients who were receiving primarily cisplatin." | 3.67 | Effective control of chemotherapy-induced nausea and vomiting with oral prednisone and metoclopramide. ( Bachmann-Mettler, I; Glaus, A; Senn, HJ, 1984) |
| "Metoclopramide infusions are used to prevent nausea and vomiting in cancer patients during chemotherapy." | 3.67 | Population analysis of the pharmacokinetic variability of high-dose metoclopramide in cancer patients. ( Bateman, DN; Grevel, J; Kelman, AW; Taylor, WB; Whiting, B, 1988) |
| "In two previous consecutive studies on antiemetic combination of metoclopramide and dexamethasone was found to be very active against nausea and vomiting induced by cisplatin (DDP; 50 mg/m2) alone or in combination with other cytotoxic emetogenic drugs." | 3.67 | Maintenance of antiemetic effect of a metoclopramide-dexamethasone combination during subsequent cisplatin courses. ( Caporali, C; Carlini, P; Cognetti, F; Pinnarò, P; Ruggeri, EM, 1986) |
| "Sixteen of 26 patients given 51 courses of treatment of the doxorubicin and cisplatin combination with no antiemetic therapy suffered the same number of vomiting episodes and had the same duration of vomiting as did the remaining ten patients given 20 cycles of this chemotherapy plus the standard high-dose metoclopramide regimen." | 3.67 | Lack of antiemetic effect of high-dose metoclopramide. ( Christiansen, NP; Hrushesky, WJ; Roemeling, RV, 1985) |
| "Nausea and emesis are common side effects of opioid drugs administered for pain relief in cancer patients." | 2.70 | A double-blind, randomised, parallel group, multinational, multicentre study comparing a single dose of ondansetron 24 mg p.o. with placebo and metoclopramide 10 mg t.d.s. p.o. in the treatment of opioid-induced nausea and emesis in cancer patients. ( Albertsson, M; Chimontsi-Kypriou, V; Curtis, P; Daly, S; Hardy, J; McQuade, B; Stathopoulos, P, 2002) |
| "Metoclopramide was given i." | 2.68 | Ondansetron versus metoclopramide as antiemetic treatment during cisplatin-based chemotherapy. A prospective study with special regard to regard to electrolyte imbalance. ( Benou, N; Charalambidis, G; Ganas, N; Karabellis, A; Kosmidis, P; Mylonakis, N; Pagou, M; Tsavaris, N; Tsikalakis, D, 1995) |
| "Thirty patients with advanced cancer, who were no longer receiving antineoplastic therapy, were randomly assigned to receive either L 75 mg/day or M 30 mg/day." | 2.68 | Effectiveness of levosulpiride versus metoclopramide for nausea and vomiting in advanced cancer patients: a double-blind, randomized, crossover study. ( Battaiotto, L; Corli, O; Cozzolino, A, 1995) |
| "Midazolam is an effective benzodiazepine with a rapid onset and short duration of action, properties that could permit its use in outpatient areas or in short but stressful situations." | 2.67 | Midazolam in patients receiving anticancer chemotherapy and antiemetics. ( Baltzer, L; Clark, RA; Gralla, RJ; Kris, MG; Pisters, KM; Potanovich, LM; Tyson, LB, 1993) |
| " Tropisetron in combination with dexamethasone produced the best control of both acute and delayed emesis." | 2.67 | Prevention of chemotherapy-induced nausea and vomiting by tropisetron (Navoban) alone or in combination with other antiemetic agents. ( Bruntsch, U; Drechsler, S; Eggert, J; Faerber, L; Gosse, H; Imhoff, W; Ukena, D, 1994) |
| "Emesis is one of the most frequent and distressing adverse effects of cytotoxic chemotherapy." | 2.67 | Prevention of emesis by tropisetron (Navoban) in children receiving cytotoxic therapy for solid malignancies. ( Balduck, N; Hachimi-Idrissi, S; Maurus, R; Otten, J, 1994) |
| "Acute nausea was prevented completely in 40% of patients in the tropisetron group and in 61% of the metoclopramide cocktail group during course 1 (P < ." | 2.67 | Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience. ( Sorbe, BG, 1994) |
| "289 consecutive cancer patients receiving cisplatin chemotherapy (much greater than 50 mg/m2) were randomised to receive one of the following intravenous antiemetic regimens: ondansetron 0." | 2.67 | Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis. Italian Group For Antiemetic Research. ( , 1992) |
| "Vomiting was decreased in the DXM groups compared to groups A and C (p < 0." | 2.67 | Antiemetic efficacy of high-dose metoclopramide and dexamethasone in patients receiving cisplatin chemotherapy: a randomized trial. ( Bacoyannis, C; Droufakou, S; Kosmidis, P; Kozatsani-Halividi, D; Mylonakis, N; Tsaroucha-Noutsou, E; Tsavaris, N; Tsoutsos, H; Valilis, P, 1992) |
| " Only one adverse event, headache, occurred in more than five patients in the granisetron group." | 2.67 | Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. The Granisetron Study Group. ( Chevallier, B, 1990) |
| "Sixty-nine patients with malignant tumors receiving cancer chemotherapy, 90% including cis-platinum, were evaluated in a randomized crossover study for the antiemetic efficacy and the side effects of two antiemetic regimens: chlorpromazine (CPM) 2." | 2.66 | Chlorpromazine and dexamethasone versus high-dose metoclopramide and dexamethasone in patients receiving cancer chemotherapy, particularly cis-platinum: a prospective randomized crossover study. ( Ben-Yosef, R; Biran, S; Brufman, G; Catane, R; Gez, E, 1989) |
| " However, in the group of patients who received a high dosage of cisplatin (70-100 mg/m2), or ethylenediamine platinum II malonate (800-900 mg/m2), there was a significant difference in nausea and vomiting between patients who had and those who had not received prior chemotherapy, most probably due to anticipation." | 2.66 | Comparison of two different high doses of metoclopramide in the prevention of chemotherapy-induced emesis. ( Gall, HE; Knobf, MK; Nauta, J; Pinedo, HM; Simons, KA; van Groeningen, CJ; van Loenen, AC; Vermorken, JB, 1989) |
| "Continuous infusion of metoclopramide was compared with bolus dosing in a randomized, double-blind study in 27 patients receiving cisplatin therapy." | 2.66 | Continuous i.v. infusion versus multiple bolus doses of metoclopramide for prevention of cisplatin-induced emesis. ( Agostinucci, WA; Dinonno, EB; Gannon, RH; Golub, GR; Martin, RS; Schauer, PK, 1988) |
| "Metoclopramide serum levels were measured by high-performance liquid chromatography." | 2.66 | Antiemetic effect of oral versus intravenous metoclopramide in patients receiving cisplatin: a randomized, double-blind trial. ( Anthony, LB; Brenner, DE; Burish, TG; Greco, FA; Hainsworth, JD; Hande, KR; Krozely, MG; Woodward, NJ, 1986) |
| "In a randomized trial of 58 cancer patients receiving strongly emetogenic cytostatic drugs (cisplatin or comparable cytostatic agents, alone or in combination), the anti-emetic action of oral metoclopramide was tested, alone or combined with prednisone." | 2.66 | [Prevention of nausea and emesis during cytostatic therapy. Antiemetic efficacy of high-dosage oral metoclopramide without and with prednisone]. ( Bachmann-Mettler, I; Glaus, A; Köhler, M; Senn, HJ; Weigand, W, 1986) |
| "Metoclopramide was more effective in decreasing the volume of emesis than was alizapride (median of 100 ml vs." | 2.66 | The antiemetic activity of high-dose alizapride and high-dose metoclopramide in patients receiving cancer chemotherapy: a prospective, randomized, double-blind trial. ( Bischoff, AK; Brunner, KW; Galeazzi, RL; Joss, RA; Pirovino, M; Ryssel, HJ, 1986) |
| " The biological half-life of metoclopramide was 9." | 2.66 | Antiemetic effect and pharmacokinetics of high dose metoclopramide in cancer patients treated with cisplatin-containing chemotherapy regimens. ( Havsteen, H; Kjaer, M; Nielsen, H, 1986) |
| " Its optimal dosage schedule, however, has not yet been completely defined." | 2.66 | Antiemetic activity of two different high doses of metoclopramide in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research. ( Ballatori, E; Basurto, C; Canaletti, R; Colombo, N; DiCostanzo, F; Donati, D; Morsia, D; Passalacqua, R; Roila, F; Tonato, M, 1985) |
| "In a population of 51 ambulant cancer patients treated with doxorubicin-containing chemotherapy we conducted a double-blind cross-over randomized trial, comparing the anti-emetic efficacy of a combination of amitriptyline (25 mg p." | 2.65 | Amitriptyline plus fluphenazine to prevent chemotherapy-induced emesis in cancer patients: a double-blind randomized cross-over study. ( Blijham, GH; Mellink, WA; van Deyk, WA, 1984) |
| "Metoclopramide was superior to placebo and to prochlorperazine in reducing the volume of emesis (P = 0." | 2.65 | Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. ( Bordin, LA; Braun, DW; Braun, TJ; Gralla, RJ; Itri, LM; Kelsen, DP; Pisko, SE; Squillante, AE; Young, CW, 1981) |
| " The importance of adequate dosage of metoclopramide and the role of IV metoclopramide are emphasized." | 2.65 | Metoclopramide in the reduction of nausea and vomiting associated with combined chemotherapy. ( Cox, R; Leyland, MJ; Newman, CE, 1982) |
| "Anamorelin HCl is a highly selective, novel ghrelin receptor agonist." | 2.61 | Prokinetics and ghrelin for the management of cancer cachexia syndrome. ( Malik, JS; Yennurajalingam, S, 2019) |
| "Nausea is a common symptom in advanced cancer, with a prevalence of up to 70%." | 2.55 | Corticosteroids for adult patients with advanced cancer who have nausea and vomiting (not related to chemotherapy, radiotherapy, or surgery). ( Good, P; Hardy, JR; Haywood, A; Khan, S; Rickett, K; Vayne-Bossert, P, 2017) |
| "Nausea and vomiting are debilitating side effects that often accompany the administration of chemotherapy and may lead to adverse physiological and psychological effects." | 2.39 | Antiemetics in children receiving cancer chemotherapy. ( Billett, AL; Sallan, SE, 1994) |
| " In this study, we aimed to detect, document, and descriptively analyze the potential drug-drug interactions in hospitalized solid tumor's patients in a Middle Eastern referral oncology-hematology University-affiliated hospital." | 1.62 | Potential drug-drug Interactions in hospitalized cancer patients: A report from the Middle-East. ( Adib-Majlesi, M; Hajigholami, A; Moghaddas, A; Riechelmann, R; Sabzghabaee, AM, 2021) |
| " Using a Delphi study method, physicians were asked to rank preferences of drug and dosing schedule for first-line opioid, antiemetic, and laxative for the treatment of adults with chronic pain due to cancer and other life-threatening conditions." | 1.38 | Strategic pain management: the identification and development of the IAHPC opioid essential prescription package. ( Bennett, MI; Bruera, E; De Lima, L; Nekolaichuk, C; Ripamonti, CI; Vignaroli, E; Wenk, R, 2012) |
| "Eleven advanced cancer patients affected by malignant bowel obstruction (MBO) were treated at home with a combination of octreotide, metoclopramide, morphine, and dexamethasone." | 1.37 | Can malignant bowel obstruction in advanced cancer patients be treated at home? ( Aielli, F; Ficorella, C; Galletti, B; Porzio, G; Shoja E Razavi, G; Verna, L, 2011) |
| "Metoclopramide has the greatest evidence for efficacy followed by phenothiazines and tropisetron." | 1.36 | Nausea and vomiting in advanced cancer. ( Ang, SK; Davis, MP; Shoemaker, LK, 2010) |
| "The kinetics and bioavailability of a new formulation of metoclopramide (CAS 364-62-5) nasal spray (MTC NS) were assessed in two separate studies versus the same drug administered intravenously (MTC IV) according to a balanced-block design where each study subject served as his own control." | 1.29 | Pharmacokinetics and bioavailability of metoclopramide nasal spray versus metoclopramide intravenous in healthy volunteers and cancer patients. ( Dimaiuta, M; Ferrari, P; Fraschini, F; Scaglione, F; Scanni, A; Tomirotti, M, 1993) |
| " Thus, controlling the adverse side effects associated with radiation therapy is critical to optimal patient care." | 1.29 | Controlling the toxicity of palliative radiotherapy: the role of 5-HT3 antagonists. ( Priestman, TJ, 1996) |
| "Nausea and emesis during cancer chemotherapy are very common, but can often be controlled with repetitive boli of antiemetic drugs." | 1.28 | Patient-controlled antiemesis for cancer chemotherapy-induced nausea and vomiting. ( Naji, P; Osterwalder, B; Schuler, L; Senn, HJ; Wilder-Smith, CH, 1990) |
| "Metoclopramide is a very effective drug in preventing the acute emetic and nauseating effects of cisplatin." | 1.28 | Suitability of long-acting metoclopramide for prophylaxis of chemotherapy-induced delayed nausea and vomiting. ( Schimke, J; Senn, HJ; Vergin, H; Wilder-Smith, C, 1989) |
| "Metoclopramide was given in 4 doses of 1mg/kg on the same schedule." | 1.28 | [Antiemetic efficacy of betamethasone versus betamethasone combined with metoclopramide in cisplatin-treated cancer patients]. ( Kagami, Y; Narimatsu, N; Nishio, M; Sakurai, T; Tomita, M, 1989) |
| " At the same time about 1/3 of these serious adverse drug reactions (ADR) was found to have been reported to the ADR-register." | 1.27 | Drug utilization and morbidity statistics for the evaluation of drug safety in Sweden. ( Westerholm, B; Wiholm, BE, 1984) |
| "In a randomized crossover study 57 cancer patients receiving chemotherapy with high emetic potential were treated with low-dose levonantradol or standard-dose metoclopramide and crossed over to the other antiemetic drug in the next identical chemotherapy cycle." | 1.27 | Randomized crossover study of the antiemetic activity of levonantradol and metoclopramide in cancer patients receiving chemotherapy. ( Altenburg, HP; Heim, ME; Queisser, W, 1984) |
| "Metoclopramide was given intravenously (IV) at a dose of 0." | 1.27 | Combination metoclopramide and dexamethasone: an effective antiemetic regimen in outpatients receiving non-cisplatin chemotherapy. ( McDermed, JE; McDermott, NM; Streng, BR; Strum, SB, 1984) |
| "With increasingly effective cancer chemotherapy, the control of chemotherapy-induced nausea and vomiting has become more important." | 1.27 | Control of cancer chemotherapy-induced nausea and vomiting. ( Eyre, HJ; Ward, JH, 1984) |
| " Metoclopramide and methylprednisolone, at the dosage and schedule used, were well tolerated and moderately active in preventing nausea and vomiting induced by cis-platin; their use in combination could further improve these results." | 1.27 | Comparison of methylprednisolone and metoclopramide in the prophylactic treatment of cis-platin-induced nausea and vomiting. ( Bertetto, O; Calciati, A; Ciuffreda, L; Clerico, M; Donadio, M; Ferrati, P; Giaccone, G; Musella, R, 1984) |
| "Nausea and vomiting are often severe and prolonged, rendering a patient unfit for further treatment." | 1.27 | [New aspects in the antiemetic therapy of cytostatic drug-induced vomiting]. ( Gerhartz, H; Hiller, E, 1984) |
| " The quantitative dose-response curves of the four doses of the emetic agonist cisplatin were shifted to the right by increasing doses of MCL." | 1.27 | Dose-response relationships of the objective and subjective antiemetic effects and of different side effects of metoclopramide against cisplatin induced emesis. ( Hellenbrecht, D; Saller, R, 1986) |
| "Nausea and vomiting are common complications of cisplatin chemotherapy." | 1.27 | Evaluation of ethanol as an antiemetic in patients receiving cisplatin. ( Adelstein, DJ; Hines, JD; Spiess, JL, 1987) |
| "Metoclopramide (MCP) was used as an antiemetic agent in 11 pediatric oncology patients during 22 courses of cancer therapy including cisplatin, doxorubicin, and other agents." | 1.27 | Metoclopramide as an antiemetic agent in pediatric oncology patients. ( Blatt, J; Felix, C; Howrie, DL; Juhl, RP; Wollman, M, 1986) |
| "The metoclopramide regimens were well tolerated and, with the exception of two patients, were completely effective in the prevention of nausea and vomiting." | 1.27 | The pharmacokinetics of high dose metoclopramide in patients with neoplastic disease. ( Addis, GJ; Bryson, SM; Kelman, AW; McGovern, EM; White, K; Whiting, B, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 71 (43.56) | 18.7374 |
| 1990's | 57 (34.97) | 18.2507 |
| 2000's | 15 (9.20) | 29.6817 |
| 2010's | 15 (9.20) | 24.3611 |
| 2020's | 5 (3.07) | 2.80 |
| Authors | Studies |
|---|---|
| Harder, S | 2 |
| Groenvold, M | 2 |
| Herrstedt, J | 3 |
| Moghaddas, A | 1 |
| Adib-Majlesi, M | 1 |
| Sabzghabaee, AM | 1 |
| Hajigholami, A | 1 |
| Riechelmann, R | 1 |
| Radhakrishnan, V | 1 |
| Pai, V | 1 |
| Rajaraman, S | 1 |
| Mehra, N | 1 |
| Ganesan, T | 1 |
| Dhanushkodi, M | 1 |
| Perumal Kalaiyarasi, J | 1 |
| Rajan, AK | 1 |
| Selvarajan, G | 1 |
| Ranganathan, R | 1 |
| Karunakaran, P | 1 |
| Sagar, TG | 1 |
| Kaneishi, K | 1 |
| Imai, K | 1 |
| Nishimura, K | 1 |
| Sakurai, N | 1 |
| Kohara, H | 1 |
| Ishiki, H | 1 |
| Kanai, Y | 1 |
| Oyamada, S | 1 |
| Yamaguchi, T | 1 |
| Morita, T | 1 |
| Iwase, S | 1 |
| Davis, M | 1 |
| Hui, D | 1 |
| Davies, A | 1 |
| Ripamonti, C | 1 |
| Capela, A | 1 |
| DeFeo, G | 1 |
| Del Fabbro, E | 1 |
| Bruera, E | 7 |
| Vayne-Bossert, P | 1 |
| Haywood, A | 1 |
| Good, P | 1 |
| Khan, S | 1 |
| Rickett, K | 1 |
| Hardy, JR | 1 |
| Sutherland, A | 1 |
| Naessens, K | 1 |
| Plugge, E | 1 |
| Ware, L | 1 |
| Head, K | 1 |
| Burton, MJ | 1 |
| Wee, B | 1 |
| Malik, JS | 1 |
| Yennurajalingam, S | 1 |
| Isaksen, J | 1 |
| Neergaard, MA | 1 |
| Frandsen, K | 1 |
| Sigaard, J | 1 |
| Mondrup, L | 1 |
| Jespersen, BA | 1 |
| Keat, CH | 2 |
| Phua, G | 1 |
| Abdul Kassim, MS | 1 |
| Poh, WK | 1 |
| Sriraman, M | 1 |
| Ghani, NA | 1 |
| Tsukuura, H | 1 |
| Ando, Y | 1 |
| Gyawali, B | 1 |
| Matsumoto, M | 1 |
| Sugishita, M | 1 |
| Honda, K | 1 |
| Urakawa, H | 1 |
| Maeda, O | 1 |
| Hasegawa, Y | 1 |
| Smith, LA | 1 |
| Azariah, F | 1 |
| Lavender, VT | 1 |
| Stoner, NS | 1 |
| Bettiol, S | 1 |
| Waqar, SN | 1 |
| Mann, J | 1 |
| Baggstrom, MQ | 1 |
| Waqar, MA | 1 |
| Chitneni, P | 1 |
| Williams, K | 1 |
| Gao, F | 1 |
| Morgensztern, D | 1 |
| Govindan, R | 1 |
| Hawkins, R | 1 |
| Grunberg, S | 1 |
| Pikó, B | 1 |
| Bassam, A | 1 |
| Ang, SK | 1 |
| Shoemaker, LK | 1 |
| Davis, MP | 3 |
| Zang, J | 1 |
| Hou, M | 1 |
| Gou, HF | 1 |
| Qiu, M | 1 |
| Wang, J | 1 |
| Zhou, XJ | 1 |
| Luo, de Y | 1 |
| Yang, Y | 1 |
| Jiang, M | 1 |
| Cao, D | 1 |
| Bi, F | 1 |
| Xu, F | 1 |
| Shen, Y | 1 |
| Yi, C | 1 |
| Porzio, G | 1 |
| Aielli, F | 1 |
| Verna, L | 1 |
| Galletti, B | 1 |
| Shoja E Razavi, G | 1 |
| Ficorella, C | 1 |
| Perwitasari, DA | 1 |
| Wessels, JA | 1 |
| van der Straaten, RJ | 1 |
| Baak-Pablo, RF | 1 |
| Mustofa, M | 1 |
| Hakimi, M | 1 |
| Nortier, JW | 1 |
| Gelderblom, H | 1 |
| Guchelaar, HJ | 1 |
| Vignaroli, E | 1 |
| Bennett, MI | 1 |
| Nekolaichuk, C | 1 |
| De Lima, L | 1 |
| Wenk, R | 1 |
| Ripamonti, CI | 1 |
| Navari, RM | 1 |
| Nagy, CK | 1 |
| Gray, SE | 1 |
| Wilson, J | 1 |
| Plourde, JY | 1 |
| Marshall, D | 1 |
| Yoshida, S | 1 |
| Chow, W | 1 |
| Harsanyi, Z | 4 |
| Pearen, S | 1 |
| Darke, A | 3 |
| Aapro, MS | 3 |
| Thuerlimann, B | 1 |
| Sessa, C | 1 |
| De Pree, C | 1 |
| Bernhard, J | 1 |
| Maibach, R | 1 |
| Lelli, G | 1 |
| Montanari, M | 1 |
| Gilli, G | 1 |
| Scapoli, D | 2 |
| Antonietti, C | 1 |
| Bhatia, A | 2 |
| Tripathi, KD | 2 |
| Sharma, M | 2 |
| Moyano, JR | 1 |
| Sala, R | 1 |
| Rico, MA | 1 |
| Bosnjak, S | 1 |
| Bertolino, M | 1 |
| Willey, J | 1 |
| Strasser, F | 1 |
| Palmer, JL | 1 |
| Acharya, MR | 1 |
| Sparreboom, A | 1 |
| Sausville, EA | 1 |
| Conley, BA | 1 |
| Doroshow, JH | 1 |
| Venitz, J | 1 |
| Figg, WD | 1 |
| Yavuzsen, T | 1 |
| Walsh, D | 1 |
| LeGrand, S | 1 |
| Lagman, R | 1 |
| Roila, F | 4 |
| Basurto, C | 3 |
| Bracarda, S | 2 |
| Del Favero, A | 3 |
| Tonato, M | 4 |
| Nagula, S | 1 |
| Schattner, M | 1 |
| Colls, BM | 1 |
| Kotlarek-Haus, S | 1 |
| Orzechowska-Juzwenko, K | 1 |
| Gabryś, K | 1 |
| Williams, CJ | 1 |
| Bolton, A | 1 |
| de Pemberton, R | 1 |
| Whitehouse, JM | 1 |
| Gralla, RJ | 3 |
| Tyson, LB | 2 |
| Bordin, LA | 2 |
| Clark, RA | 2 |
| Kelsen, DP | 2 |
| Kris, MG | 2 |
| Kalman, LB | 1 |
| Groshen, S | 1 |
| Gagen, M | 1 |
| Gochnour, D | 1 |
| Young, D | 1 |
| Gaginella, T | 1 |
| Neidhart, J | 1 |
| Mellink, WA | 1 |
| Blijham, GH | 1 |
| van Deyk, WA | 1 |
| Allan, SG | 2 |
| Cornbleet, MA | 2 |
| Lockhart, SP | 1 |
| Warrington, PS | 3 |
| Leonard, RC | 2 |
| Smyth, JF | 3 |
| Wiholm, BE | 1 |
| Westerholm, B | 1 |
| Heim, ME | 1 |
| Queisser, W | 1 |
| Altenburg, HP | 1 |
| Strum, SB | 3 |
| McDermed, JE | 3 |
| Streng, BR | 1 |
| McDermott, NM | 1 |
| Eyre, HJ | 1 |
| Ward, JH | 1 |
| Senn, HJ | 4 |
| Glaus, A | 2 |
| Bachmann-Mettler, I | 2 |
| Plezia, PM | 3 |
| Alberts, DS | 3 |
| Graham, V | 2 |
| Jones, SE | 1 |
| Surwit, EA | 2 |
| Moon, TE | 1 |
| Grunberg, SM | 1 |
| Gala, KV | 1 |
| Lampenfeld, M | 1 |
| Jamin, D | 1 |
| Johnson, K | 1 |
| Cariffe, P | 1 |
| Strych, D | 1 |
| Krailo, M | 1 |
| Giaccone, G | 2 |
| Donadio, M | 1 |
| Musella, R | 1 |
| Bertetto, O | 2 |
| Ciuffreda, L | 1 |
| Ferrati, P | 1 |
| Clerico, M | 2 |
| Calciati, A | 1 |
| Murakami, M | 2 |
| Kessler, J | 1 |
| Budach, V | 1 |
| Krüger, K | 1 |
| Terrin, BN | 1 |
| McWilliams, NB | 1 |
| Maurer, HM | 1 |
| Hiller, E | 1 |
| Gerhartz, H | 1 |
| Melsom, H | 1 |
| Nandrup, E | 1 |
| Monge, OR | 1 |
| Ise, T | 1 |
| Ohira, M | 1 |
| Omiya, A | 1 |
| Hirose, M | 1 |
| Shibata, T | 1 |
| Daniels, M | 1 |
| Belt, RJ | 1 |
| Itri, LM | 1 |
| Pisko, SE | 1 |
| Squillante, AE | 1 |
| Braun, DW | 1 |
| Braun, TJ | 1 |
| Young, CW | 1 |
| Cox, R | 1 |
| Newman, CE | 1 |
| Leyland, MJ | 1 |
| Cook, RJ | 1 |
| Cubeddu, LX | 1 |
| Hoffmann, IS | 1 |
| Tsavaris, N | 3 |
| Charalambidis, G | 1 |
| Ganas, N | 1 |
| Pagou, M | 1 |
| Karabellis, A | 1 |
| Mylonakis, N | 3 |
| Benou, N | 1 |
| Tsikalakis, D | 1 |
| Kosmidis, P | 3 |
| Potanovich, LM | 1 |
| Pisters, KM | 1 |
| Baltzer, L | 1 |
| Bruera, ED | 1 |
| MacEachern, TJ | 1 |
| Spachynski, KA | 1 |
| LeGatt, DF | 1 |
| MacDonald, RN | 1 |
| Babul, N | 3 |
| Darke, AC | 1 |
| Billett, AL | 1 |
| Sallan, SE | 1 |
| Hesketh, PJ | 2 |
| Pater, J | 1 |
| Slamet, L | 1 |
| Zee, B | 1 |
| Osoba, D | 1 |
| Warr, D | 1 |
| Rusthoven, J | 1 |
| Cefalo, G | 1 |
| Rottoli, L | 1 |
| Armiraglio, A | 1 |
| Pagan, MG | 1 |
| Fleishman, SB | 1 |
| Lavin, MR | 1 |
| Sattler, M | 1 |
| Szarka, H | 1 |
| Laplanche, A | 1 |
| Gérondeau, N | 1 |
| Scaglione, F | 1 |
| Scanni, A | 1 |
| Tomirotti, M | 1 |
| Dimaiuta, M | 1 |
| Ferrari, P | 1 |
| Fraschini, F | 1 |
| Sorbe, BG | 2 |
| Högberg, T | 1 |
| Glimelius, B | 1 |
| Schmidt, M | 1 |
| Wernstedt, L | 1 |
| Hansen, O | 1 |
| Sörensen, BT | 1 |
| Räisänen, I | 1 |
| van Oosterom, AT | 1 |
| de Bruijn, KM | 1 |
| Morandini, MP | 1 |
| Cardinali, C | 1 |
| Nelson, KA | 1 |
| Walsh, TD | 1 |
| Chevallier, B | 3 |
| Hirst, DG | 1 |
| Joiner, B | 1 |
| Hirst, VK | 1 |
| Corli, O | 1 |
| Cozzolino, A | 1 |
| Battaiotto, L | 1 |
| Gebbia, V | 1 |
| Testa, A | 1 |
| Valenza, R | 1 |
| Cannata, G | 1 |
| Tirrito, ML | 1 |
| Gebbia, N | 1 |
| Basade, M | 1 |
| Kulkarni, SS | 1 |
| Dhar, AK | 1 |
| Sastry, PS | 1 |
| Saikia, B | 1 |
| Advani, SH | 2 |
| Seifert, L | 1 |
| Watanabe, S | 1 |
| Suarez-Almazor, M | 1 |
| Priestman, TJ | 1 |
| Cappelaere, P | 1 |
| Splinter, T | 1 |
| Fabbro, M | 1 |
| Wendling, JL | 1 |
| Cals, L | 1 |
| Catimel, G | 1 |
| Giovannini, M | 1 |
| Khayat, D | 1 |
| Bastit, P | 1 |
| Claverie, N | 1 |
| Chang, CS | 1 |
| Chen, LT | 1 |
| Huang, SM | 1 |
| Liu, TC | 1 |
| Lin, SF | 1 |
| Chen, TP | 1 |
| Wei, TC | 1 |
| Madej, G | 1 |
| Krzakowski, M | 1 |
| Pawinski, A | 1 |
| Lasota, W | 1 |
| Rogowski, W | 1 |
| Skoneczna, I | 1 |
| Bruntsch, U | 1 |
| Drechsler, S | 1 |
| Eggert, J | 1 |
| Gosse, H | 1 |
| Ukena, D | 1 |
| Imhoff, W | 1 |
| Faerber, L | 1 |
| Otten, J | 1 |
| Hachimi-Idrissi, S | 1 |
| Balduck, N | 1 |
| Maurus, R | 1 |
| Tavorath, R | 1 |
| Regnard, CF | 1 |
| O'Reilly, M | 1 |
| Heberer, M | 1 |
| Mystakidou, K | 1 |
| Befon, S | 1 |
| Liossi, C | 1 |
| Vlachos, L | 1 |
| Ballatori, E | 3 |
| Berto, P | 1 |
| De Angelis, V | 1 |
| Neri, C | 1 |
| Olivieri, A | 1 |
| Plosker, GL | 1 |
| Milne, RJ | 1 |
| Belzile, M | 1 |
| Neumann, C | 1 |
| Negro, S | 1 |
| Azuara, ML | 1 |
| Sánchez, Y | 1 |
| Reyes, R | 1 |
| Barcia, E | 1 |
| Hardy, J | 1 |
| Daly, S | 1 |
| McQuade, B | 1 |
| Albertsson, M | 1 |
| Chimontsi-Kypriou, V | 1 |
| Stathopoulos, P | 1 |
| Curtis, P | 1 |
| Klepp, O | 1 |
| Ottesen, S | 1 |
| Monrad, L | 1 |
| Dogliotti, L | 1 |
| Antonacci, RA | 1 |
| Pazè, E | 1 |
| Ortega, C | 1 |
| Berruti, A | 1 |
| Faggiuolo, R | 1 |
| Ding, DC | 1 |
| Castle, WM | 1 |
| Cunningham, K | 1 |
| Kanarek, BB | 1 |
| Tsaroucha-Noutsou, E | 2 |
| Bacoyannis, C | 2 |
| Valilis, P | 1 |
| Kozatsani-Halividi, D | 2 |
| Tsoutsos, H | 2 |
| Droufakou, S | 1 |
| Buxton, MJ | 1 |
| O'Brien, BJ | 1 |
| Gorter, R | 1 |
| Karvounis, N | 1 |
| Klinaki, A | 1 |
| González Barón, M | 1 |
| Chacón, JI | 1 |
| García Girón, C | 1 |
| Ordóñez Gallego, A | 1 |
| García de Paredes, ML | 1 |
| Feliu, J | 1 |
| Zamora, P | 1 |
| Herranz, C | 1 |
| Garrido, P | 1 |
| Artal, A | 1 |
| Akhtar, SS | 1 |
| Bano, ZA | 1 |
| Bhat, GM | 1 |
| Bhat, MA | 1 |
| Kaasa, S | 1 |
| Mella, O | 1 |
| Kvikstad, A | 1 |
| Adamski, P | 1 |
| Kessler, JF | 1 |
| Berens, PL | 1 |
| Chase, JL | 1 |
| Roe, DJ | 1 |
| Picciafuoco, M | 1 |
| Wilder-Smith, CH | 1 |
| Schuler, L | 1 |
| Osterwalder, B | 1 |
| Naji, P | 1 |
| Smaldone, L | 1 |
| Plezia, P | 1 |
| Alberts, D | 1 |
| Aapro, M | 1 |
| Sartiano, G | 1 |
| Dorn, M | 1 |
| Brady, M | 1 |
| Comerski, C | 1 |
| Schwartz, SE | 1 |
| Fairchild, C | 1 |
| Hardy, F | 1 |
| MacPherson, JS | 2 |
| Hudson, SA | 1 |
| Jefferson, GC | 1 |
| Federico, M | 1 |
| Sabbatini, R | 1 |
| Piccinini, P | 1 |
| Zironi, S | 1 |
| Piccinini, L | 1 |
| Silingardi, V | 1 |
| Brenneis, C | 1 |
| Michaud, M | 1 |
| MacDonald, N | 1 |
| Wilder-Smith, C | 1 |
| Schimke, J | 1 |
| Vergin, H | 1 |
| Gez, E | 1 |
| Ben-Yosef, R | 1 |
| Catane, R | 1 |
| Brufman, G | 1 |
| Biran, S | 1 |
| Culine, S | 1 |
| Azab, M | 1 |
| Pietri, F | 1 |
| Ghosn, M | 1 |
| Ben Amor, B | 1 |
| Lupera, H | 1 |
| Theodore, C | 1 |
| Renaux, J | 1 |
| Droz, JP | 1 |
| van Groeningen, CJ | 1 |
| Gall, HE | 1 |
| Simons, KA | 1 |
| van Loenen, AC | 1 |
| Knobf, MK | 1 |
| Nauta, J | 1 |
| Vermorken, JB | 1 |
| Pinedo, HM | 1 |
| Kagami, Y | 1 |
| Nishio, M | 1 |
| Narimatsu, N | 1 |
| Tomita, M | 1 |
| Sakurai, T | 1 |
| Ballmer, PE | 1 |
| Reinhart, WH | 1 |
| Hatae, Y | 1 |
| Takeda, T | 1 |
| Nakadate, H | 1 |
| Hatayama, Y | 1 |
| Kishino, T | 1 |
| Ogawa, Y | 1 |
| Cunningham, D | 1 |
| Bradley, CJ | 1 |
| Forrest, GJ | 1 |
| Hutcheon, AW | 1 |
| Adams, L | 1 |
| Sneddon, M | 1 |
| Harding, M | 1 |
| Kerr, DJ | 1 |
| Soukop, M | 1 |
| Kaye, SB | 1 |
| Ota, K | 1 |
| Parikh, PM | 1 |
| Charak, BS | 1 |
| Banavali, SD | 1 |
| Koppikar, SB | 1 |
| Giri, N | 1 |
| Nadkarni, P | 1 |
| Saikia, TK | 1 |
| Gopal, R | 1 |
| Sorbe, B | 1 |
| Hallén, C | 1 |
| Furste, AB | 1 |
| Gutterman, L | 1 |
| Pritchard, JD | 1 |
| Wheeler, W | 1 |
| Enck, RE | 1 |
| Parashos, PJ | 2 |
| Dugan, WM | 2 |
| Fry, MW | 2 |
| Sridhar, KS | 1 |
| Donnelly, E | 1 |
| Shiu, W | 1 |
| Tsang, V | 1 |
| Lam, YM | 1 |
| Zacharia, A | 1 |
| Martin, WM | 1 |
| Taylor, WB | 2 |
| Simpson, JM | 1 |
| Bateman, DN | 2 |
| Grevel, J | 1 |
| Whiting, B | 2 |
| Kelman, AW | 2 |
| Agostinucci, WA | 1 |
| Gannon, RH | 1 |
| Golub, GR | 1 |
| Martin, RS | 2 |
| Schauer, PK | 2 |
| Dinonno, EB | 1 |
| Anthony, LB | 1 |
| Krozely, MG | 1 |
| Woodward, NJ | 1 |
| Hainsworth, JD | 1 |
| Hande, KR | 1 |
| Brenner, DE | 1 |
| Greco, FA | 1 |
| Burish, TG | 1 |
| Köhler, M | 1 |
| Weigand, W | 1 |
| Saller, R | 3 |
| Hellenbrecht, D | 3 |
| Bühring, M | 1 |
| Hess, H | 1 |
| Joss, RA | 1 |
| Galeazzi, RL | 1 |
| Bischoff, AK | 1 |
| Pirovino, M | 1 |
| Ryssel, HJ | 1 |
| Brunner, KW | 1 |
| Rhinehart, SN | 1 |
| Triplett, WC | 1 |
| Minnick, DJ | 1 |
| Spiess, JL | 1 |
| Adelstein, DJ | 1 |
| Hines, JD | 1 |
| Presant, CA | 1 |
| Wiseman, C | 1 |
| Gala, K | 1 |
| Kennedy, P | 1 |
| Bouzaglou, A | 1 |
| Blayney, D | 1 |
| Schindler, J | 1 |
| Rigas, M | 1 |
| Melville, J | 1 |
| Dolan, J | 1 |
| Frustaci, S | 1 |
| Grattoni, E | 1 |
| Tumolo, S | 1 |
| Crivellari, D | 1 |
| Figoli, F | 1 |
| Galligioni, E | 1 |
| Veronesi, A | 1 |
| Tirelli, U | 1 |
| Grigoletto, E | 1 |
| Cognetti, F | 1 |
| Carlini, P | 1 |
| Pinnarò, P | 1 |
| Ruggeri, EM | 1 |
| Caporali, C | 1 |
| Havsteen, H | 1 |
| Nielsen, H | 1 |
| Kjaer, M | 1 |
| Jordan, NS | 1 |
| Schauer, A | 1 |
| Nightingale, C | 1 |
| Golub, G | 1 |
| Williams, HM | 1 |
| Sawamura, N | 2 |
| Funaki, Y | 1 |
| Takahashi, S | 2 |
| Yokoyama, S | 2 |
| Fujita, J | 2 |
| Futami, H | 2 |
| Sasaki, Y | 2 |
| Yoshioka, S | 1 |
| Sakurai, M | 1 |
| Eguchi, K | 1 |
| Shinkai, T | 1 |
| Saijo, N | 1 |
| Funaki, U | 1 |
| Shimizu, E | 1 |
| Pruitt, BT | 1 |
| Justice, RL | 1 |
| Periman, P | 1 |
| Cohen, JL | 1 |
| Joseph, C | 1 |
| Canaletti, R | 1 |
| Morsia, D | 1 |
| Passalacqua, R | 1 |
| DiCostanzo, F | 1 |
| Donati, D | 1 |
| Colombo, N | 1 |
| Israel, R | 1 |
| O'Mara, V | 1 |
| Austin, B | 1 |
| Bellucci, A | 1 |
| Meyer, BR | 1 |
| Howrie, DL | 1 |
| Felix, C | 1 |
| Wollman, M | 1 |
| Juhl, RP | 1 |
| Blatt, J | 1 |
| Bryson, SM | 1 |
| McGovern, EM | 1 |
| White, K | 1 |
| Addis, GJ | 1 |
| Liponi, DF | 1 |
| Roemeling, RV | 1 |
| Christiansen, NP | 1 |
| Hrushesky, WJ | 1 |
| Alavi, JB | 1 |
| Torri, S | 1 |
| Glover, D | 1 |
| Hurwitz, S | 1 |
| Glick, JH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Olanzapine, Netupitant and Palonosetron in Controlling Nausea and Vomiting Associated With Highly Emetogenic Chemotherapy in Patients With Breast Cancer[NCT04669132] | Phase 2 | 50 participants (Actual) | Interventional | 2020-12-17 | Completed | ||
| A Randomized, Double-Blind Trial to Compare the Clinical Efficacy and Safety of Granisetron vs. Metoclopramide Combined to Dexamethasone in the Prophylaxis of Chemotherapy-Induced Delayed Emesis[NCT00003213] | Phase 3 | 267 participants (Actual) | Interventional | 1996-05-31 | Completed | ||
| Effectiveness and Quality of Life Analysis of Palonosetron Against Ondansetron Combined With Dexamethasone and Fosaprepitant in Prevention of Acute and Delayed Emesis Associated to Chemotherapy Moderate and Highly Emetogenic in Breast Cancer.[NCT03606369] | Phase 2/Phase 3 | 560 participants (Anticipated) | Interventional | 2015-11-05 | Recruiting | ||
| 5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence[NCT01549652] | 133 participants (Actual) | Interventional | 2011-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Beck Depression Inventory (a 21-item self-report multiple-choice inventory) yields a single summed score between 0 and 63; higher scores indicate more severe depression. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken prior to receiving ondansetron or placebo, at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) |
|---|---|
| Prevention of Opioid Withdrawal | -0.44 |
The VAS is a 0 to 100 millimeter scale where 0 corresponds to no pain and 100 to extreme pain, used by participants to indicated their level of pain over the last two weeks. Change is from baseline score for average level of pain (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken prior to receiving ondansetron or placebo, at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) |
|---|---|
| Prevention of Opioid Withdrawal | -2.68 |
The Roland-Morris Disability Index is a 24-question instrument used to assess level of disability from lower back pain. Scores range from 0-24 with lower scores corresponding to fewer symptoms. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken prior to receiving ondansetron or placebo, at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) |
|---|---|
| Prevention of Opioid Withdrawal | -2.59 |
The Beck Depression Inventory (a 21-item self-report multiple-choice inventory) yields a single summed score between 0 and 63; higher scores indicate more severe depression. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in BDIS (Ondansetron) | Change in BDIS (Placebo) | |
| Prevention of Physical Dependence | -0.6 | 0.2 |
"Originally developed by Handelsman, the Objective Opioid Withdrawal Scale (OOWS) score is a well-characterized measure of opioid withdrawal in humans, calculated as the sum of a 13-item physician assessment documenting physically observable signs of withdrawal, which are rated as present (1) or absent (0) during the observation period. The minimum score of 0 means the patient is not showing any signs of opioid withdrawal. The maximum score of 13 signifies all signs of opioid withdrawal to the largest extent possible.~Immediately prior to ondansetron or placebo administration a baseline OOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an OOWS score was taken. If deemed necessary by the clinician, participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an OOWS score was taken. Change from the baseline OOWS score to the score assessed following the last naloxone dose is reported." (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in OOWS (Ondansetron) | Change in OOWS (Placebo) | |
| Prevention of Opioid Withdrawal | 3.6 | 3.6 |
"Originally developed by Handelsman, the OOWS score is a well-characterized measure of opioid withdrawal in humans, calculated as the sum of a 13-item physician assessment documenting physically observable signs of withdrawal, which are rated as present (1) or absent (0) during the observation period. The maximum score is 13 and suggests the patient is showing all signs of opioid withdrawal to the largest extent possible. The minimum score of 0 suggests the patient is not showing any signs of opioid withdrawal.~Immediately prior to ondansetron or placebo administration a baseline OOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an OOWS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an OOWS score was taken. Change from the baseline OOWS score to the score assessed following the last naloxone dose is reported." (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in OOWS (Ondansetron) | Change in OOWS (Placebo) | |
| Prevention of Physical Dependence | 4.5 | 4.2 |
The VAS is a 0 to 100 millimeter scale where 0 corresponds to no pain and 100 to extreme pain, used by participants to indicated their level of pain over the last two weeks. Change is from baseline score for average level of pain (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in VAS Score (Ondansetron) | Change in VAS Score (Placebo) | |
| Prevention of Physical Dependence | -2.9 | -2.8 |
The Roland-Morris Disability Index is a 24-question instrument used to assess level of disability from lower back pain. Scores range from 0-24 with lower scores corresponding to fewer symptoms. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in RMDI (Ondansetron) | Change in RMDI (Placebo) | |
| Prevention of Physical Dependence | -4.6 | -2.0 |
The Subjective Opioid Withdrawal Score (SOWS) score is calculated as the sum of 16 subjective patient-reported symptom scores rated on a scale of 0 to 4 (0=not at all, 4=extremely) based on what subjects were experiencing at the time of testing. A maximum score of 64 would suggest the patient is experiencing the symptoms of withdrawal to the maximum extent possible while the lowest score of 0 would suggest the patient is not experiencing any of the symptoms of withdrawal. Immediately prior to ondansetron or placebo administration a baseline SOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an SOWS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an SOWS score was taken. Change from the baseline SOWS score to the score assessed following the last naloxone dose is reported (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in SOWS (Ondansetron) | Change in SOWS (Placebo) | |
| Prevention of Opioid Withdrawal | 12.5 | 12.2 |
The SOWS score is composed of 16 subjective symptoms rated on a scale of 0 to 4 (0=not at all, 4=extremely) based on what subjects were experiencing at the time of testing. A maximum score of 64 would suggest the patient is experiencing the symptoms of withdrawal to the maximum extent possible while the lowest score of 0 would suggest the patient is not experiencing any of the symptoms of withdrawal. Immediately prior to ondansetron or placebo administration a baseline SOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an SOWS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an SOWS score was taken. Change from the baseline SOWS score to the score assessed following the last naloxone dose is reported (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in SOWS (Ondansetron) | Change in SOWS (Placebo) | |
| Prevention of Physical Dependence | 16.4 | 12.0 |
Profile of Mood States (POMS) is a 65-question survey of how participants have been feeling over the past week, assessing tension, depression, anger, fatigue, confusion and vigor. Each question is on a 5-point scale: 0 (not at all) to 4 (extremely). Overall score range: 0 to 200 (lower scores corresponding to fewer symptoms), calculated by adding total scores for tension, depression, anger, fatigue and confusing, and subtracting that total score from the total score for vigor. Immediately prior to ondansetron or placebo administration a baseline POMS score was taken. 30 minutes later participants received naloxone, then 15 minutes later a POMS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an POMS score was taken. Change from the baseline POMS score to the score assessed following the last naloxone dose is reported. (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in POMS Score (Ondansetron) | Change in POMS Score (Placebo) | |
| Prevention of Opioid Withdrawal | 29.3 | 28.3 |
(Profile of Mood States) POMS is a 65-question survey of how participants have been feeling over the past week, assessing tension, depression, anger, fatigue, confusion and vigor. Each question is on a 5-point scale: 0 (not at all) to 4 (extremely). Overall score range: 0 to 200 (lower scores corresponding to fewer symptoms), calculated by adding total scores for tension, depression, anger, fatigue and confusing, and subtracting that total score from the total score for vigor. Immediately prior to ondansetron or placebo administration a baseline POMS score was taken. 30 minutes later participants received naloxone, then 15 minutes later a POMS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an POMS score was taken. Change from the baseline POMS score to the score assessed following the last naloxone dose is reported. (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in POMS (Ondansetron) | Change in POMS (Placebo) | |
| Prevention of Physical Dependence | 36.1 | 29.2 |
27 reviews available for metoclopramide and Neoplasms
| Article | Year |
|---|---|
MASCC antiemetics in advanced cancer updated guideline.
Topics: Antiemetics; Humans; Metoclopramide; Nausea; Neoplasms; Vomiting | 2021 |
Corticosteroids for adult patients with advanced cancer who have nausea and vomiting (not related to chemotherapy, radiotherapy, or surgery).
Topics: Adrenal Cortex Hormones; Adult; Chlorpromazine; Dexamethasone; Humans; Indoles; Metoclopramide; Naus | 2017 |
Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults.
Topics: Adult; Antiemetics; Antineoplastic Agents; Benzodiazepines; Chemoradiotherapy; Dexamethasone; Disord | 2018 |
Prokinetics and ghrelin for the management of cancer cachexia syndrome.
Topics: Cachexia; Forecasting; Gastrointestinal Agents; Ghrelin; Humans; Hydrazines; Metoclopramide; Neoplas | 2019 |
Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Agents; Cannabinoids; Chlorpromazine; Dizziness; Domperidone; Eup | 2015 |
Chemotherapy-induced nausea and vomiting: challenges and opportunities for improved patient outcomes.
Topics: Antiemetics; Antineoplastic Agents; Humans; Metoclopramide; Nausea; Neoplasms; Substance P; Treatmen | 2009 |
[Treatment of tumor therapy-induced nausea and vomiting].
Topics: Anti-Anxiety Agents; Antiemetics; Antineoplastic Agents; Aprepitant; Drug Therapy, Combination; Huma | 2009 |
Long-term safety and clinical effectiveness of controlled-release metoclopramide in cancer-associated dyspepsia syndrome: a multicentre evaluation.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Anorexia; Antiemetics; Delayed-Action Preparat | 2002 |
Treatment of the cancer anorexia-cachexia syndrome: a critical reappraisal.
Topics: Anorexia; Cachexia; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Male; Medro | 2003 |
Systematic review of the treatment of cancer-associated anorexia and weight loss.
Topics: Adrenal Cortex Hormones; Adult; Anorexia; Antiemetics; Appetite Stimulants; Humans; Metoclopramide; | 2005 |
Antiemetic therapy in patients treated with cisplatin chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Controlled Clinical Trials as Topic; Double-Blind Met | 1989 |
Development of antiemetic therapy in cancer patients.
Topics: Antiemetics; Dopamine Antagonists; Humans; Metoclopramide; Neoplasms; Serotonin Antagonists; Steroid | 1995 |
Antiemetics in children receiving cancer chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Child; Dexamethasone; Humans; Metoclopramide; Nausea; Neoplasms; | 1994 |
Treatment of chemotherapy-induced emesis in the 1990s: impact of the 5-HT3 receptor antagonists.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Humans; Metoclopramide; Nausea; Neopla | 1994 |
Inconsistency of prognostic factors for post-chemotherapy nausea and vomiting.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Doxorubicin; Female; Granisetron; Huma | 1994 |
[Role of ondansetron in oncology].
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Dose-Response Relationship, Drug; Drug | 1993 |
Drug treatment of chemotherapy-induced delayed emesis.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Humans; Metoclopramide; Nausea; Neopla | 1996 |
[Tumor cachexia--a special entity and therapeutic sequelae].
Topics: Cachexia; Combined Modality Therapy; Energy Metabolism; Enteral Nutrition; Humans; Metoclopramide; N | 1997 |
Pharmacological treatment of cachexia: any progress?
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Antiemetics; Antioxidants; Appetite Stimulants; C | 1998 |
Prevention of chemotherapy- and radiotherapy-induced emesis: results of Perugia Consensus Conference. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC).
Topics: Adult; Antiemetics; Antineoplastic Agents; Child; Dexamethasone; Humans; Metoclopramide; Neoplasms; | 1998 |
Ondansetron: a pharmacoeconomic and quality-of-life evaluation of its antiemetic activity in patients receiving cancer chemotherapy.
Topics: Costs and Cost Analysis; Drug Therapy; Drug Tolerance; Economics, Pharmaceutical; Forecasting; Formu | 1992 |
Management of anorexia-cachexia associated with cancer and HIV infection.
Topics: Anorexia; Antineoplastic Agents; Cachexia; Dronabinol; HIV Infections; Humans; Hydrazines; Megestrol | 1991 |
[Nausea and vomiting during treatment with cytostatics].
Topics: Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Metoclop | 1991 |
Batanopride (BMY-25801): a new 5-HT3 receptor antagonist for the prevention of cancer chemotherapy-induced emesis.
Topics: Animals; Antiemetics; Antineoplastic Agents; Cisplatin; Dogs; Dopamine Antagonists; Female; Ferrets; | 1990 |
[Recent advances in the management of chemotherapy-induced emesis].
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Domperidone; Dronabinol; Drug Therapy, | 1986 |
Combination antiemetics for cisplatin chemotherapy.
Topics: Antiemetics; Cisplatin; Dexamethasone; Diphenhydramine; Droperidol; Drug Evaluation; Drug Therapy, C | 1988 |
[The control of chemotherapy-induced nausea and vomiting].
Topics: Antiemetics; Antineoplastic Agents; Chemoreceptor Cells; Chlorpromazine; Cisplatin; Domperidone; Hum | 1985 |
78 trials available for metoclopramide and Neoplasms
| Article | Year |
|---|---|
Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced vomiting in children: An open-label, randomized phase 3 trial.
Topics: Adolescent; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Fe | 2020 |
Can granisetron injection used as primary prophylaxis improve the control of nausea and vomiting with low- emetogenic chemotherapy?
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Dexamethasone; Drug Therapy, Combination; Female; G | 2013 |
Antiemetic activity of megestrol acetate in patients receiving chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Studies; Drug Therapy | 2011 |
The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Benzodiazepines; Cis | 2013 |
Long-term safety and clinical effectiveness of controlled-release metoclopramide in cancer-associated dyspepsia syndrome: a multicentre evaluation.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Anorexia; Antiemetics; Delayed-Action Preparat | 2002 |
A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemother | 2003 |
Comparison of ondansetron with metoclopramide in prevention of acute emesis associated with low dose & high dose cisplatin chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Female; Humans; Male; Met | 2003 |
Dexamethasone in addition to metoclopramide for chronic nausea in patients with advanced cancer: a randomized controlled trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiemetics; Chronic Disease; Dexamethasone; D | 2004 |
Efficacy & tolerability of ondansetron compared to metoclopramide in dose dependent cisplatin-induced delayed emesis.
Topics: Adult; Antiemetics; Cisplatin; Dexamethasone; Dose-Response Relationship, Drug; Drug Therapy, Combin | 2004 |
Cannabis and cancer chemotherapy.
Topics: Antiemetics; Clinical Trials as Topic; Dronabinol; Humans; Metoclopramide; Neoplasms; Research Desig | 1980 |
Antiemetics for patients treated with antitumor chemotherapy.
Topics: Adolescent; Adult; Aged; Antiemetics; Cisplatin; Cyclizine; Dronabinol; Drug Therapy, Combination; F | 1980 |
Antiemetic therapy: a review of recent studies and a report of a random assignment trial comparing metoclopramide with delta-9-tetrahydrocannabinol.
Topics: Antiemetics; Antineoplastic Agents; Clinical Trials as Topic; Dronabinol; Humans; Metoclopramide; Ne | 1984 |
A randomized trial of metoclopramide and a combination of dexamethasone and lorazepam for prevention of chemotherapy-induced vomiting.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; D | 1984 |
Amitriptyline plus fluphenazine to prevent chemotherapy-induced emesis in cancer patients: a double-blind randomized cross-over study.
Topics: Adult; Amitriptyline; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Doub | 1984 |
Emesis due to cancer chemotherapy: results of a prospective, randomised, double-blind trial of varying doses of metoclopramide in the management of cis-platinum-induced vomiting.
Topics: Adolescent; Adult; Aged; Cisplatin; Clinical Trials as Topic; Double-Blind Method; Female; Humans; M | 1984 |
Double-blind crossover study of the antiemetic efficacy of high-dose dexamethasone versus high-dose metoclopramide.
Topics: Adult; Aged; Antiemetics; Basal Ganglia Diseases; Cisplatin; Dexamethasone; Double-Blind Method; Dru | 1984 |
Comparison of the antiemetic effect of high-dose intravenous metoclopramide and high-dose intravenous haloperidol in a randomized double-blind crossover study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Double-Blind Method; Drug Evaluati | 1984 |
[Alizapride in a double-blind trial with metoclopramide in nausea and vomiting caused by radiotherapy].
Topics: Adolescent; Adult; Aged; Antiemetics; Appetite; Double-Blind Method; Female; Humans; Male; Metoclopr | 1983 |
[Metoclopramide (Primperan) versus droperidol (Dridol) as an antiemetic in intravenous cancer chemotherapy].
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Clinical Trials as Topic; Double-Blind Method; Drop | 1982 |
[Clinical evaluation of antiemetics for vomiting due to cancer chemotherapy in children].
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Clinical Trials as Topic; D | 1982 |
Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting.
Topics: Adult; Aged; Cisplatin; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; Metoclo | 1981 |
Metoclopramide in the reduction of nausea and vomiting associated with combined chemotherapy.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Hum | 1982 |
Ondansetron versus metoclopramide as antiemetic treatment during cisplatin-based chemotherapy. A prospective study with special regard to regard to electrolyte imbalance.
Topics: Adult; Aged; Cisplatin; Drug Therapy, Combination; Female; Humans; Male; Metoclopramide; Middle Aged | 1995 |
Midazolam in patients receiving anticancer chemotherapy and antiemetics.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Dexamethasone; Drug Therapy, Com | 1993 |
Comparison of the efficacy, safety, and pharmacokinetics of controlled release and immediate release metoclopramide for the management of chronic nausea in patients with advanced cancer.
Topics: Chronic Disease; Delayed-Action Preparations; Double-Blind Method; Humans; Metoclopramide; Nausea; N | 1994 |
Inconsistency of prognostic factors for post-chemotherapy nausea and vomiting.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Doxorubicin; Female; Granisetron; Huma | 1994 |
A randomized, multicenter study comparing the efficacy and tolerability of tropisetron, a new 5-HT3 receptor antagonist, with a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Cisplatin; Female; Humans; Indoles; Male; Metoclopramid | 1994 |
Antiemetic activity of oral lorazepam in addition to methylprednisolone and metoclopramide in the prophylactic treatment of vomiting induced by cisplatin. A double-blind, placebo-controlled study with crossover design.
Topics: Adult; Aged; Cisplatin; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Lorazepam; M | 1993 |
Metoclopramide in anorexia caused by cancer-associated dyspepsia syndrome (CADS).
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anorexia; Dyspepsia; Female; Gastrointestinal | 1993 |
The control of acute cisplatin-induced emesis--a comparative study of granisetron and a combination regimen of high-dose metoclopramide and dexamethasone. Granisetron Study Group.
Topics: Blood Pressure; Cisplatin; Dexamethasone; Drug Therapy, Combination; Female; Granisetron; Humans; In | 1993 |
Effectiveness of levosulpiride versus metoclopramide for nausea and vomiting in advanced cancer patients: a double-blind, randomized, crossover study.
Topics: Aged; Antiemetics; Cross-Over Studies; Double-Blind Method; Female; Gastrointestinal Agents; Humans; | 1995 |
Oral granisetron with or without methylprednisolone versus metoclopramide plus methylprednisolone in the management of delayed nausea and vomiting induced by cisplatin-based chemotherapy. A prospective randomized trial.
Topics: Administration, Oral; Adult; Aged; Antiemetics; Cisplatin; Drug Therapy, Combination; Female; Granis | 1995 |
Comparison of dexamethasone and metoclopramide as antiemetics in children receiving cancer chemotherapy.
Topics: Adolescent; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cr | 1996 |
Chronic nausea in advanced cancer patients: a retrospective assessment of a metoclopramide-based antiemetic regimen.
Topics: Aged; Antiemetics; Antineoplastic Agents; Female; Humans; Male; Metoclopramide; Nausea; Neoplasms; R | 1996 |
A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy.
Topics: Acute Disease; Alcoholism; Antiemetics; Antineoplastic Agents; Basal Ganglia Diseases; Cisplatin; Do | 1997 |
A report comparing the use of tropisetron (Navoban), a 5-HT3 antagonist, with a standard antiemetic regimen of dexamethasone and metoclopramide in cisplatin-treated patients under conditions of severe emesis.
Topics: Adult; Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Dopamine Antagonists; Double-Bl | 1994 |
Prevention of chemotherapy-induced nausea and vomiting by tropisetron (Navoban) alone or in combination with other antiemetic agents.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Dexamethasone; Dopamine Antagonists; Drug Therapy, | 1994 |
Prevention of emesis by tropisetron (Navoban) in children receiving cytotoxic therapy for solid malignancies.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Dopamine Antagonists; Femal | 1994 |
Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Dexamethasone; Dopamine Antagonists; Drug Therapy, | 1994 |
Comparison of the efficacy and safety of tropisetron, metoclopramide, and chlorpromazine in the treatment of emesis associated with far advanced cancer.
Topics: Adult; Aged; Antiemetics; Chlorpromazine; Dexamethasone; Drug Therapy, Combination; Female; Humans; | 1998 |
A double-blind, crossover study of controlled-release metoclopramide and placebo for the chronic nausea and dyspepsia of advanced cancer.
Topics: Aged; Antiemetics; Chronic Disease; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; M | 2000 |
A double-blind, randomised, parallel group, multinational, multicentre study comparing a single dose of ondansetron 24 mg p.o. with placebo and metoclopramide 10 mg t.d.s. p.o. in the treatment of opioid-induced nausea and emesis in cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Antiemetics; Double-Blind Method; Female; Humans | 2002 |
Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis. Italian Group For Antiemetic Research.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiemetics; Cisplatin; Clinical Protocols; De | 1992 |
Three years' experience with tropisetron in the control of nausea and vomiting in cisplatin-treated patients.
Topics: Adult; Aged; Antiemetics; Cisplatin; Female; Humans; Indoles; Lorazepam; Male; Metoclopramide; Middl | 1992 |
Antiemetic efficacy of high-dose metoclopramide and dexamethasone in patients receiving cisplatin chemotherapy: a randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Dose-Response | 1992 |
Economic evaluation of ondansetron: preliminary analysis using clinical trial data prior to price setting.
Topics: Adult; Aged; Antineoplastic Agents; Costs and Cost Analysis; Double-Blind Method; Drug Industry; Fem | 1992 |
Antiemetic regimens in outpatients receiving cisplatin and non-cisplatin chemotherapy. A randomized trial comparing high-dose metoclopramide plus methylprednisolone with and without lorazepam.
Topics: Antineoplastic Agents; Cisplatin; Drug Therapy, Combination; Female; Humans; Lorazepam; Male; Methyl | 1991 |
A double-blind randomized cross-over comparison of high-dose prochlorperazine with high-dose metoclopramide for cisplatin-induced emesis.
Topics: Adult; Cisplatin; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Mal | 1991 |
Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. The Granisetron Study Group.
Topics: Cisplatin; Dexamethasone; Drug Therapy, Combination; Female; Granisetron; Headache; Humans; Indazole | 1990 |
Randomized crossover comparison of high-dose intravenous metoclopramide versus a five-drug antiemetic regimen.
Topics: Adult; Aged; Cisplatin; Dexamethasone; Diazepam; Diphenhydramine; Drug Therapy, Combination; Humans; | 1990 |
A pharmacokinetic study of high-dose metoclopramide suppositories.
Topics: Administration, Rectal; Biological Availability; Female; Humans; Lung Neoplasms; Male; Metoclopramid | 1990 |
Chlorpromazine and dexamethasone versus high-dose metoclopramide and dexamethasone in patients receiving cancer chemotherapy, particularly cis-platinum: a prospective randomized crossover study.
Topics: Adolescent; Adult; Aged; Antiemetics; Chlorpromazine; Cisplatin; Clinical Trials as Topic; Dexametha | 1989 |
[A phase III trial comparing the antiemetic activity of tetracosactide with dexamethasone in combination with metoclopramide, diphenhydramine and clorazepate during chemotherapy including cisplatin].
Topics: Adult; Aged; Cisplatin; Clinical Trials as Topic; Clorazepate Dipotassium; Cosyntropin; Dexamethason | 1989 |
Comparison of two different high doses of metoclopramide in the prevention of chemotherapy-induced emesis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Do | 1989 |
Does parenteral magnesium sulfate have an antiemetic effect during chemotherapy with cis-platinum?
Topics: Adolescent; Adult; Aged; Antiemetics; Cisplatin; Diazepam; Double-Blind Method; Drug Evaluation; Dru | 1989 |
A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues.
Topics: Adolescent; Adult; Aged; Antiemetics; Cisplatin; Clinical Trials as Topic; Dexamethasone; Dronabinol | 1988 |
A prospective, randomized double-blind trial comparing metoclopramide alone with metoclopramide plus dexamethasone in preventing emesis induced by high-dose cisplatin.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Dexameth | 1988 |
Betamethasone-dixyrazine versus metoclopramide as antiemetic treatment in cancer chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Betamethasone; Clinical Trials as Topic; Double-Blind Method; Hu | 1988 |
A pilot study comparing decadron (D)/ativan (A) versus reglan (R)/decadron (D)/benadryl (B) as antiemetic regimens.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials | 1988 |
Continuous infusion metoclopramide: clinical trials, pharmacokinetic considerations and cost-effectiveness.
Topics: Cisplatin; Clinical Trials as Topic; Cost-Benefit Analysis; Humans; Infusions, Intravenous; Metoclop | 1987 |
A randomised cross-over trial comparing low-dose metoclopramide and chlorpromazine with high-dose metoclopramide in Chinese patients with advanced cancer receiving cisplatinum and 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorpromazine; Cisplatin; Clinical Tri | 1987 |
High-dose metoclopramide by infusion: a double-blind study of plasma concentration-effect relationships in patients receiving cancer chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Doub | 1987 |
Continuous i.v. infusion versus multiple bolus doses of metoclopramide for prevention of cisplatin-induced emesis.
Topics: Adult; Aged; Aged, 80 and over; Cisplatin; Female; Humans; Infusions, Intravenous; Injections, Intra | 1988 |
Antiemetic effect of oral versus intravenous metoclopramide in patients receiving cisplatin: a randomized, double-blind trial.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 1986 |
[Prevention of nausea and emesis during cytostatic therapy. Antiemetic efficacy of high-dosage oral metoclopramide without and with prednisone].
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cis | 1986 |
Enhancement of the antiemetic action of metoclopramide against cisplatin-induced emesis by transdermal electrical nerve stimulation.
Topics: Adult; Aged; Cisplatin; Clinical Trials as Topic; Double-Blind Method; Electric Stimulation; Female; | 1986 |
The antiemetic activity of high-dose alizapride and high-dose metoclopramide in patients receiving cancer chemotherapy: a prospective, randomized, double-blind trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Do | 1986 |
The value of dexamethasone when added to combination drug therapy in the prevention of cisplatin-induced nausea and vomiting, evaluated by time-lapse video technology.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Dexamethasone; | 1986 |
Randomized crossover antiemetic study in cisplatin-treated patients. Comparison between high-dose i.v. metoclopramide and high-dose i.v. dexamethasone.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Female; Human | 1986 |
Antiemetic effect and pharmacokinetics of high dose metoclopramide in cancer patients treated with cisplatin-containing chemotherapy regimens.
Topics: Adult; Cisplatin; Female; Half-Life; Humans; Kinetics; Male; Metoclopramide; Middle Aged; Neoplasms; | 1986 |
Optimising antiemesis in cancer chemotherapy: efficacy of continuous versus intermittent infusion of high dose metoclopramide in emesis induced by cisplatin.
Topics: Adult; Aged; Cisplatin; Female; Humans; Infusions, Parenteral; Male; Metoclopramide; Middle Aged; Na | 1986 |
The effect of administration rate on cisplatin-induced emesis.
Topics: Adult; Aged; Cisplatin; Clinical Trials as Topic; Double-Blind Method; Drug Administration Schedule; | 1985 |
[Randomized control study of high-dose metoclopramide in the prevention of CDDP-induced emesis].
Topics: Adult; Aged; Cisplatin; Clinical Trials as Topic; Female; Humans; Infusions, Parenteral; Male; Metoc | 1985 |
Comparative evaluation of two outpatient antiemetic regimens for cancer chemotherapy.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Dexamethasone; Humans; Metoclopramide; Nausea; Neop | 1985 |
Clinical pharmacokinetics of high-dose metoclopramide in cancer patients receiving cisplatin therapy.
Topics: Adult; Aged; Cisplatin; Clinical Trials as Topic; Dexamethasone; Drug Therapy, Combination; Female; | 1985 |
Antiemetic activity of two different high doses of metoclopramide in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research.
Topics: Adult; Age Factors; Aged; Cisplatin; Clinical Trials as Topic; Double-Blind Method; Female; Humans; | 1985 |
High-dose intravenous metoclopramide versus combination high-dose metoclopramide and intravenous dexamethasone in preventing cisplatin-induced nausea and emesis: a single-blind crossover comparison of antiemetic efficacy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; | 1985 |
[Benefit and risk of high-dose metoclopramide in comparison to high-dose haloperidol or triflupromazine in cisplatin-induced vomiting].
Topics: Cisplatin; Dose-Response Relationship, Drug; Haloperidol; Humans; Metoclopramide; Neoplasms; Risk; T | 1985 |
60 other studies available for metoclopramide and Neoplasms
| Article | Year |
|---|---|
Reply to: Olanzapine: Sancho Panza for clinicians who care for patients with advanced cancer.
Topics: Antiemetics; Humans; Male; Metoclopramide; Nausea; Neoplasms; Olanzapine; Vomiting | 2020 |
Potential drug-drug Interactions in hospitalized cancer patients: A report from the Middle-East.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cross-Sectional Studies; Dopamine | 2021 |
Olanzapine versus Metoclopramide for Treatment of Nausea and Vomiting in Advanced Cancer Patients with Incomplete Malignant Bowel Obstruction.
Topics: Antiemetics; Double-Blind Method; Humans; Metoclopramide; Nausea; Neoplasms; Olanzapine; Vomiting | 2020 |
The nature of nausea: prevalence, etiology, and treatment in patients with advanced cancer not receiving antineoplastic treatment.
Topics: Adrenal Cortex Hormones; Adult; Age Factors; Aged; Aged, 80 and over; Antiemetics; Female; Humans; M | 2019 |
Cost-effectiveness analysis of granisetron-based versus standard antiemetic regimens in low-emetogenic chemotherapy: a hospital-based perspective from Malaysia.
Topics: Antiemetics; Antineoplastic Agents; Cost-Benefit Analysis; Dexamethasone; Drug Therapy, Combination; | 2013 |
Prophylactic Use of Antiemetics for Prevention of Opioid-Induced Nausea and Vomiting: A Questionnaire Survey among Japanese Physicians.
Topics: Analgesics, Opioid; Antiemetics; Benzodiazepines; Chemoprevention; Domperidone; Health Care Surveys; | 2015 |
Delayed nausea and vomiting from carboplatin doublet chemotherapy.
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Lora | 2016 |
Nausea and vomiting in advanced cancer.
Topics: Algorithms; Antiemetics; Causality; Decision Trees; Drug Therapy, Combination; Evidence-Based Medici | 2010 |
Can malignant bowel obstruction in advanced cancer patients be treated at home?
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Antiemetics; Dexamethasone; Drug Therapy, Combin | 2011 |
Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Casse | 2011 |
Strategic pain management: the identification and development of the IAHPC opioid essential prescription package.
Topics: Analgesics, Opioid; Antiemetics; Clinical Protocols; Constipation; Delphi Technique; Dioctyl Sulfosu | 2012 |
Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor.
Topics: Animals; Area Under Curve; Benzamides; Binding, Competitive; Blood Proteins; Dogs; Glycoproteins; Ha | 2006 |
Malignant gastroparesis: diagnostics and therapeutics.
Topics: Anti-Bacterial Agents; Antiemetics; Erythromycin; Gastroparesis; Humans; Metoclopramide; Neoplasms | 2007 |
[Vomiting accompanying cytostatic treatment, and its control].
Topics: Antiemetics; Antineoplastic Agents; Dronabinol; Drug Evaluation; Histamine H1 Antagonists; Humans; M | 1984 |
Drug utilization and morbidity statistics for the evaluation of drug safety in Sweden.
Topics: Acidosis; Aged; Anti-Infective Agents, Urinary; Biguanides; Congenital Abnormalities; Contraceptives | 1984 |
Randomized crossover study of the antiemetic activity of levonantradol and metoclopramide in cancer patients receiving chemotherapy.
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents; Drug Therapy, Combination; Female; Huma | 1984 |
Combination metoclopramide and dexamethasone: an effective antiemetic regimen in outpatients receiving non-cisplatin chemotherapy.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Ad | 1984 |
Control of cancer chemotherapy-induced nausea and vomiting.
Topics: Antineoplastic Agents; Butyrophenones; Cannabinoids; Drug Therapy, Combination; Glucocorticoids; Hum | 1984 |
Effective control of chemotherapy-induced nausea and vomiting with oral prednisone and metoclopramide.
Topics: Administration, Oral; Adult; Cisplatin; Dose-Response Relationship, Drug; Drug Therapy, Combination; | 1984 |
Comparison of methylprednisolone and metoclopramide in the prophylactic treatment of cis-platin-induced nausea and vomiting.
Topics: Adult; Aged; Cisplatin; Drug Evaluation; Female; Humans; Male; Methylprednisolone; Metoclopramide; M | 1984 |
[Gastrointestinal disturbance by cancer chemotherapy--recent progress in antiemetic regimens].
Topics: Adult; Aged; Animals; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Domper | 1984 |
Immediate termination of intractable vomiting induced by cisplatin combination chemotherapy using an intensive five-drug antiemetic regimen.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Diazepam; Dip | 1984 |
Side effects of metoclopramide as an antiemetic in childhood cancer chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Dystonia; Female; Humans; Male; Metoclopramide; Nau | 1984 |
[New aspects in the antiemetic therapy of cytostatic drug-induced vomiting].
Topics: Antiemetics; Antineoplastic Agents; Cannabinoids; Chemoreceptor Cells; Dose-Response Relationship, D | 1984 |
High dose metoclopramide as an antiemetic for patients receiving chemotherapy with cis-platinum.
Topics: Adult; Cisplatin; Drug Evaluation; Humans; Metoclopramide; Nausea; Neoplasms; Vomiting | 1982 |
Interim analyses in 2 x 2 crossover trials.
Topics: Antiemetics; Antineoplastic Agents; Biometry; Clinical Trials as Topic; Cross-Over Studies; Humans; | 1995 |
Participation of serotonin on early and delayed emesis induced by initial and subsequent cycles of cisplatinum-based chemotherapy: effects of antiemetics.
Topics: Adult; Cisplatin; Dexamethasone; Dose-Response Relationship, Drug; Female; Humans; Hydroxyindoleacet | 1993 |
Tropisetron (ICS 205-930) in pediatric oncology: first results in patients refractory to antiemetic metoclopramide-based treatments.
Topics: Adolescent; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Child; Female; Humans; Indo | 1994 |
Antiemetic-induced akathisia in cancer patients receiving chemotherapy.
Topics: Akathisia, Drug-Induced; Antineoplastic Agents; Drug Therapy, Combination; Female; Humans; Male; Met | 1994 |
Pharmacokinetics and bioavailability of metoclopramide nasal spray versus metoclopramide intravenous in healthy volunteers and cancer patients.
Topics: Administration, Intranasal; Adolescent; Adult; Aerosols; Aged; Biological Availability; Humans; Inje | 1993 |
Blood flow modification by nicotinamide and metoclopramide in mouse tumours growing in different sites.
Topics: Animals; Cardiac Output; Colonic Neoplasms; Male; Mammary Neoplasms, Experimental; Metoclopramide; M | 1993 |
Controlling the toxicity of palliative radiotherapy: the role of 5-HT3 antagonists.
Topics: Antiemetics; Clinical Trials as Topic; Dopamine Antagonists; Humans; Metoclopramide; Nausea; Neoplas | 1996 |
Comparison of intravenous granisetron with metoclopramide plus dexamethasone in the prevention of nausea and vomiting associated with emetogenic cytotoxic chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Dexamethasone; Female; Granisetron; Humans; Injections, Intraven | 1997 |
Re: Metoclopramide for chronic nausea.
Topics: Antiemetics; Humans; Metoclopramide; Nausea; Neoplasms | 1997 |
Cost and cost-effectiveness analysis of ondansetron versus metoclopramide regimens: a hospital perspective from Italy.
Topics: Chemotherapy, Adjuvant; Cisplatin; Costs and Cost Analysis; Dexamethasone; Diphenhydramine; Dose-Res | 1994 |
Prevention of cisplatin-induced delayed emesis: still unsatisfactory. Italian Group for Antiemetic Research.
Topics: Adult; Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Drug Therapy, Combination; Huma | 2000 |
Physical compatibility and in vivo evaluation of drug mixtures for subcutaneous infusion to cancer patients in palliative care.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Butylscopolammonium Bromide; Dexamethasone; Drug Evaluat | 2002 |
[Cytostatic treatment and nausea-suppressing agents].
Topics: Antiemetics; Antineoplastic Agents; Humans; Metoclopramide; Nausea; Neoplasms; Prochlorperazine | 1979 |
[Morphine-antiemetics mixtures for continuous subcutaneous infusion in terminal cancer].
Topics: Antiemetics; Drug Combinations; Drug Stability; Haloperidol; Humans; Infusion Pumps, Implantable; Me | 1992 |
[Clinical multivariate statistical analysis of nephrotoxicity induced by cisplatin].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Chlorpromazine; Cisplat | 1992 |
Ondansetron is not associated with vascular adverse events, thrombocytopenia or renal failure.
Topics: Acute Kidney Injury; Cisplatin; Humans; Metoclopramide; Nausea; Neoplasms; Ondansetron; Thrombocytop | 1992 |
Antiemetic efficacy of alprazolam in carboplatin-induced emesis.
Topics: Administration, Oral; Aged; Alprazolam; Carboplatin; Drug Therapy, Combination; Female; Humans; Infu | 1991 |
Antiemetic suppositories.
Topics: Administration, Rectal; Dexamethasone; Diphenhydramine; Drug Combinations; Humans; Metoclopramide; N | 1991 |
A pilot study of metoclopramide, dexamethasone, diphenhydramine and lorazepam in prevention of nausea and vomiting in cisplatin-treated male patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Diphenhydramine; Drug Eval | 1990 |
Patient-controlled antiemesis for cancer chemotherapy-induced nausea and vomiting.
Topics: Adolescent; Adult; Antiemetics; Antineoplastic Agents; Droperidol; Evaluation Studies as Topic; Huma | 1990 |
Prevention of cisplatin-induced vomiting in patients with cancer. A pilot study with a multiagent protocol.
Topics: Cisplatin; Drug Therapy, Combination; Female; Humans; Male; Metoclopramide; Neoplasms; Pilot Project | 1990 |
Continuous Sc infusion of metoclopramide for treatment of narcotic bowel syndrome.
Topics: Colonic Diseases, Functional; Humans; Metoclopramide; Narcotics; Neoplasms; Palliative Care | 1987 |
Suitability of long-acting metoclopramide for prophylaxis of chemotherapy-induced delayed nausea and vomiting.
Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Humans; Metoclopramide; Nausea; Neoplas | 1989 |
[Antiemetic efficacy of betamethasone versus betamethasone combined with metoclopramide in cisplatin-treated cancer patients].
Topics: Adult; Aged; Antiemetics; Betamethasone; Cisplatin; Drug Evaluation; Drug Therapy, Combination; Fema | 1989 |
[The antiemetic effect and clinical evaluation of metoclopramide alone and combined with betamethasone in children with malignant tumor].
Topics: Adolescent; Adrenal Cortex; Antineoplastic Agents; Betamethasone; Child; Child, Preschool; Drug Eval | 1989 |
Population analysis of the pharmacokinetic variability of high-dose metoclopramide in cancer patients.
Topics: Antineoplastic Agents; Humans; Metoclopramide; Nausea; Neoplasms; Software | 1988 |
Dose-response relationships of the objective and subjective antiemetic effects and of different side effects of metoclopramide against cisplatin induced emesis.
Topics: Adolescent; Adult; Aged; Basal Ganglia Diseases; Cisplatin; Dose-Response Relationship, Drug; Humans | 1986 |
Evaluation of ethanol as an antiemetic in patients receiving cisplatin.
Topics: Cisplatin; Ethanol; Female; Humans; Infusions, Intravenous; Male; Metoclopramide; Nausea; Neoplasms; | 1987 |
Antiemetic effects of metoclopramide (M) continuous infusion (CI): safety, efficacy, patient preference, and cost reduction.
Topics: Cisplatin; Humans; Infusions, Intravenous; Metoclopramide; Nausea; Neoplasms; Vomiting | 1987 |
Maintenance of antiemetic effect of a metoclopramide-dexamethasone combination during subsequent cisplatin courses.
Topics: Adult; Aged; Cisplatin; Dexamethasone; Drug Combinations; Female; Humans; Male; Metoclopramide; Midd | 1986 |
Metoclopramide decreases renal plasma flow.
Topics: Aged; Blood Pressure; Cisplatin; Dopamine Antagonists; Drug Evaluation; Female; Humans; Iodohippuric | 1986 |
Metoclopramide as an antiemetic agent in pediatric oncology patients.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Female; Humans; Male; Metoclopramide; Neoplasms; Vo | 1986 |
The pharmacokinetics of high dose metoclopramide in patients with neoplastic disease.
Topics: Aged; Humans; Kinetics; Male; Metabolic Clearance Rate; Metoclopramide; Middle Aged; Neoplasms | 1985 |
Lack of antiemetic effect of high-dose metoclopramide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Female; Humans; | 1985 |
High-dose oral metoclopramide. An effective antiemetic agent.
Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Antineoplastic Combined Chemotherapy Protocols; Ci | 1985 |